<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320312459977</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320312459977</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Attenuating effect of lisinopril and telmisartan in intracerebroventricular streptozotocin induced experimental dementia of Alzheimer’s disease type: possible involvement of PPAR-γ agonistic property</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Singh</surname><given-names>Birdavinder</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Sharma</surname><given-names>Bhupesh</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Jaggi</surname><given-names>Amteshwar S</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Singh</surname><given-names>Nirmal</given-names></name>
</contrib>
<aff id="aff1-1470320312459977">Department of Pharmaceutical Sciences and Drug Research, Faculty of Medicine, Punjabi University, India</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1470320312459977">Nirmal Singh, CNS Lab., Pharmacology Division, Department of Pharmaceutical Sciences and Drug Research, Faculty of Medicine, Punjabi University, Patiala-147002, Punjab, India. Email: <email>nirmalresearch@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>14</volume>
<issue>2</issue>
<fpage>124</fpage>
<lpage>136</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>This study investigates the beneficial role of lisinopril, an angiotensin converting enzyme inhibitor (ACEI) and telmisartan, an angiotensin receptor blocker (ARB), in intracerebroventricular (i.c.v.) streptozotocin (STZ) induced dementia of Alzheimer’s disease (AD) type in mice. This study also aimed to explore the role of PPAR-γ in lisinopril and telmisartan mediated effects in i.c.v. STZ mice. Donepezil served as the positive control in the study. Mice underwent i.c.v. injection of STZ. The Morris water maze (MWM) test was employed for assessment of learning and memory. Various biochemical estimations, namely brain acetylcholinesterase (AChE) activity, myeloperoxidase (MPO) activity, nitrite/nitrate and thiobarbituric acid reactive species (TBARS) levels and reduced glutathione (GSH) levels, were also performed. The study showed that i.c.v. STZ significantly impaired learning and memory of the animals along with a significant enhancement in brain AChE, MPO, TBARS, nitrite/nitrate levels and reduction in brain GSH levels. Treatments of lisinopril/telmisartan/donepezil significantly attenuated STZ induced behavioral and biochemical changes. Pre-treatment with bisphenol-A-diglycidyl ether (BADGE), a selective PPAR-γ antagonist, significantly abolished the beneficial effect of lisinopril/telmisartan in i.c.v. STZ treated animals. The results of this investigation document a potential role of PPAR-γ in the beneficial effects of lisinopril and telmisartan in i.c.v. STZ dementia of AD type.</p>
</abstract>
<kwd-group>
<kwd>Morris water maze</kwd>
<kwd>PPAR-γ</kwd>
<kwd>oxidative stress</kwd>
<kwd>acetylcholinesterase activity</kwd>
<kwd>inflammation</kwd>
<kwd>Alzheimer’s disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320312459977" sec-type="intro">
<title>Introduction</title>
<p>The transition in world age demography towards older age is associated with an increased risk of neurodegenerative diseases, including Alzheimer’s disease (AD).<sup><xref ref-type="bibr" rid="bibr1-1470320312459977">1</xref></sup> The term ‘dementia’ refers to memory impairment and loss of other intellectual abilities which interfere with normal daily activities. Dementia of AD accounts for 50–70% of total dementia cases.<sup><xref ref-type="bibr" rid="bibr2-1470320312459977">2</xref></sup> AD is characterized by the accumulation of abnormally folded protein fragments, i.e. Aβ and tau that precipitate in amyloid plaques and neuronal tangles respectively.<sup><xref ref-type="bibr" rid="bibr3-1470320312459977">3</xref></sup> AD is the largest unmet medical need in neurology and it will reach epidemic proportions within the next 20–30 years if left unchecked. Currently, there are no treatments that prevent or slow AD.<sup><xref ref-type="bibr" rid="bibr4-1470320312459977">4</xref></sup> Current drugs improve symptoms but do not have profound disease-modifying effects.<sup><xref ref-type="bibr" rid="bibr5-1470320312459977">5</xref></sup> So, there is an urgent need to test various compounds for AD and bring therapy to individuals as early as possible.<sup><xref ref-type="bibr" rid="bibr6-1470320312459977">6</xref></sup></p>
<p>The renin-angiotensin system (RAS), an important regulator of blood pressure and mediator of hypertension-related complications, is a prime target for cardiovascular drug therapy. Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were the first drugs to be used to block the RAS.<sup><xref ref-type="bibr" rid="bibr7-1470320312459977">7</xref></sup> The RAS, already of high importance in the pathogenesis of hypertension, has become a source of interest in the pathogenesis of AD.<sup><xref ref-type="bibr" rid="bibr8-1470320312459977">8</xref></sup> Different clinical trials and studies on animal models suggest that pharmacological manipulation of the RAS may be of clinical importance in slowing or even stopping the cognitive deterioration in AD.<sup><xref ref-type="bibr" rid="bibr9-1470320312459977">9</xref></sup> Recent studies suggest that, brain-penetrating ACEIs and ARBs such as lisinopril and telmisartan are effective in providing positive cognitive effects and have shown improvement of memory.<sup><xref ref-type="bibr" rid="bibr10-1470320312459977">10</xref>,<xref ref-type="bibr" rid="bibr11-1470320312459977">11</xref></sup> It has been found that use of ACEIs and ARBs in AD patients is associated with slower rate of AD progression.<sup><xref ref-type="bibr" rid="bibr10-1470320312459977">10</xref>,<xref ref-type="bibr" rid="bibr12-1470320312459977">12</xref>,<xref ref-type="bibr" rid="bibr13-1470320312459977">13</xref></sup> However there is a controversial report saying that the use of ACEIs may be accompanied by an increase in amyloid-β (Aβ) protein (1-42) accumulation,<sup><xref ref-type="bibr" rid="bibr14-1470320312459977">14</xref></sup> the most important causative type of Aβ in AD pathogenesis.<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref><xref ref-type="bibr" rid="bibr16-1470320312459977"/>–<xref ref-type="bibr" rid="bibr17-1470320312459977">17</xref></sup> Also, it has been reported that ARBs enhance neurite outgrowth and decrease neural damage, thereby enhancing neurogenesis.<sup><xref ref-type="bibr" rid="bibr13-1470320312459977">13</xref></sup> Therefore the effectiveness of ACEIs and ARBs deserves further investigation for their therapeutic and mechanistic role in dementia of AD type.</p>
<p>Studies suggest that peroxisome proliferator-activated receptor gamma (PPAR-γ) exerts beneficial effects in patients with mild-to-moderate AD.<sup><xref ref-type="bibr" rid="bibr18-1470320312459977">18</xref>,<xref ref-type="bibr" rid="bibr19-1470320312459977">19</xref></sup> The nuclear receptor PPAR-γ is a ligand-activated transcription factor and its biological actions are to regulate glucose and lipid metabolism and suppress inflammatory gene expression.<sup><xref ref-type="bibr" rid="bibr20-1470320312459977">20</xref></sup> Currently, PPAR-γ agonists constitute an important class of insulin sensitizers as clinically employed oral antidiabetic agents. Further, PPAR-γ agonists have been reported to effectively attenuate oxidative stress, inflammation and apoptosis in the central nervous system (CNS).<sup><xref ref-type="bibr" rid="bibr21-1470320312459977">21</xref></sup> Several studies have documented that PPAR-γ activation can also prevent or attenuate neurodegeneration.<sup><xref ref-type="bibr" rid="bibr22-1470320312459977">22</xref></sup> Lisinopril and telmisartan are observed to exert hypoglycemic effects and provide beneficial effects in diabetic complications.<sup><xref ref-type="bibr" rid="bibr23-1470320312459977">23</xref><xref ref-type="bibr" rid="bibr24-1470320312459977"/>–<xref ref-type="bibr" rid="bibr25-1470320312459977">25</xref></sup> Recently both lisinopril and telmisartan have also been reported to exert potential PPAR-γ activity.<sup><xref ref-type="bibr" rid="bibr13-1470320312459977">13</xref>,<xref ref-type="bibr" rid="bibr26-1470320312459977">26</xref>,<xref ref-type="bibr" rid="bibr27-1470320312459977">27</xref></sup></p>
<p>In view of the above, the present investigation has been designed to find the beneficial role of lisinopril, an ACEI, and telmisartan, an ARB, in intracerebroventricular (i.c.v.) streptozotocin (STZ) induced dementia of AD type in mice and its modulation by bisphenol-A-diglycidyl ether (BADGE), a selective PPAR-γ antagonist. Donepezil, an acetylcholinesterase inhibitor (AChEI), served as positive control in the present study.</p>
</sec>
<sec id="section2-1470320312459977" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section3-1470320312459977">
<title>Animals</title>
<p>Swiss albino mice, weighing 20–30 grams were employed in the present study (procured from Central Research Institute, Kausali, India). They were maintained on a standard laboratory pellet chow diet (Kisan Feeds Ltd, Chandigarh, India) and water ad libitum. The animals were exposed to 12 h light and 12 h dark cycle. The experiments were conducted between 09:00 and 18:00 in a semi-soundproof laboratory. The animals were acclimatized to the laboratory condition for five days prior to the behavioral study. The protocol of the study was duly approved by the Institutional Animal Ethics Committee (IAEC) and care of the animals was carried out as per the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forests, Government of India (Reg. No. 107/1999/CPCSEA).</p>
</sec>
<sec id="section4-1470320312459977">
<title>Drugs and chemicals</title>
<p>All of the drug solutions were freshly prepared before use. Donepezil HCl was a gift from Wokhardt Ltd., Badi, India. Lisinopril and telmisartan were obtained ex-gratia from Cipla, India. STZ, BADGE and 1,1,3,3 tetra methoxy propane were purchased from Sigma Aldrich, USA. 5,5’ –dithiobis (2-nitro benzoic acid) (DTNB), bovine serum albumin (BSA), reduced glutathione (GSH), dimethylsulfoxide (DMSO) and nitrobluetetrazolium (NBT) were purchased from Sisco Research Laboratories Pvt. Ltd., Mumbai, India. Thiobarbituric acid was purchased from Loba Chemie, Mumbai, India. STZ was dissolved in artificial cerebrospinal fluid (ACSF). STZ and ACSF were delivered i.c.v. Lisinopril and telmisartan were suspended in 1% w/v of carboxymethyl cellulose (CMC). Donepezil was dissolved in saline. STZ was dissolved in 0.1 M citrate buffer (pH 4.5). BADGE was dissolved in 0.05% DMSO. Lisinopril, telmisartan and donepezil and CMC were administered orally with the help of an oral tube (cannula). BADGE and DMSO were injected intraperitoneally (i.p.). All of the drug solutions were freshly prepared before use.</p>
</sec>
<sec id="section5-1470320312459977">
<title>Induction of experimental dementia of AD by i.c.v. administration of STZ in mice</title>
<p>Experimental dementia of AD in mice was induced by i.c.v. STZ.<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref></sup> Mice were anesthetised with anesthetic ether and i.c.v. injections were made with a hypodermic needle of 0.4 mm external diameter attached to a 10 µl Hamilton microlitre syringe (Top Syringe, Mumbai, India). The needle was covered with a polypropylene tube except for 3 mm of the tip region so as to insert this portion of the needle perpendicularly through the skull into the brain of the mouse. STZ was dissolved in freshly made ACSF (25 mg/ml) solution. The injection site was 1 mm to right or left midpoint on the line drawn through to the anterior base of the ears. Injections were performed into the right or left ventricle randomly. Two doses of STZ (3 mg kg<sup>-1</sup>) were administered by i.c.v. injection bilaterally. The second dose was administered 48 h after the first dose. The concentration was adjusted so as to deliver a maximum of 5 µl in a single injection. In a similar way, control group mice were given i.c.v. injections of ACSF (147 mM NaCl; 2.9 mM KCl; 1.6 mM MgCl<sub>2</sub>, 1.7 mM dextrose).</p>
</sec>
<sec id="section6-1470320312459977">
<title>Assessment of learning and memory using the Morris water maze (MWM)</title>
<p>The MWM test was employed to assess the learning and memory of the animals.<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr28-1470320312459977">28</xref>,<xref ref-type="bibr" rid="bibr29-1470320312459977">29</xref></sup> MWM is a swimming-based model where the animal learns to escape on to a hidden platform. It consisted of a large circular pool (150 cm in diameter, 45 cm in height, filled to a depth of 30 cm with water maintained at 28±1°C). The water was made opaque with white colored non-toxic dye. The tank was divided into four equal quadrants with the help of two threads fixed at right angles to each other on the rim of the pool. A submerged platform (10 cm<sup>2</sup>;), painted in white, was placed inside the target quadrants of this pool, 1 cm below the surface of water. The position of platform was kept unaltered throughout the training session. Each animal was subjected to four consecutive training trials on each day with inter-trial gaps of 5 min. The mouse was gently placed in the water between quadrants, facing the wall of pool with the drop location changing for each trial, and allowed 120 s to locate submerged platform. The animal was allowed to stay on the platform for 20 s. If it failed to find the platform within 120 s, it was guided gently onto the platform and allowed to remain there for 20 s. Day 4 escape latency time (ELT) to locate the hidden platform in water maze was noted as an index of acquisition or learning. Each animal was subjected to four training trials each day for four consecutive days. The starting poison was changed with each exposure as mentioned below and the target quadrant (Q4) remained constant throughout the training period.</p>
<list id="list1-1470320312459977" list-type="simple"><list-item><p>Day1 Q1 Q2 Q3 Q4</p></list-item>
<list-item><p>Day2 Q2 Q3 Q4 Q1</p></list-item>
<list-item><p>Day3 Q3 Q4 Q1 Q2</p></list-item>
<list-item><p>Day4 Q4 Q1 Q2 Q3</p></list-item></list>
<p>On the fifth day, the platform was removed and each mouse was allowed to explore the pool for 120 s. The mean time spent in all four quadrants was noted. The mean time spent by the animal in the target quadrant searching for the hidden platform was noted as an index of retrieval or memory. The experimenter always stood at the same position. Care was taken regarding the relative location of the water maze with respect to other objects in the laboratory so that prominent visual clues were not disturbed during the total duration of study. All of the trials were completed between 09:00 and 18:00.</p>
</sec>
<sec id="section7-1470320312459977">
<title>Biochemical estimations</title>
<sec id="section8-1470320312459977">
<title>Collection of samples</title>
<p>Blood samples for biochemical estimation were collected by retro-orbital bleeding. The blood was kept at room temperature for 30 min and then centrifuged at 4000 rpm for 15 min to separate serum.</p>
<p>After the last retro-orbital bleeding, animals were sacrificed by cervical dislocation and the brain was carefully removed. The removed brains were homogenized in phosphate buffer (pH 7.4, 10% w/v) using Teflon homogenizer and centrifuged at 3000 rpm for 15 min to obtain clear supernatant. The serum, clear supernatant, and pellet were then used for different biochemical estimations.</p>
</sec>
<sec id="section9-1470320312459977">
<title>Estimation of brain AChE activity</title>
<p>Whole brain AChE activity was measured spectrophotometerically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 420 nm by the method of Ellman et al.<sup><xref ref-type="bibr" rid="bibr30-1470320312459977">30</xref>,<xref ref-type="bibr" rid="bibr31-1470320312459977">31</xref></sup> with slight modification.<sup><xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr29-1470320312459977">29</xref></sup> Briefly, this was measured on the basis of the formation of yellow color due to the reaction of thiocholine with dithiobisnitrobenzoate ions. The rate of formation of thiocholine from acetylthiocholine iodide in the presence of brain cholinesterase was measured using a spectrophotometer. For this, 0.5 ml of clear supernatant liquid of the brain homogenate was pipetted out into a 25 ml volumetric flask and dilution was made with a freshly prepared DTNB solution (10 mg DTNB in 100 ml of Sorenson phosphate buffer, pH 8.0). From the volumetric flask, two 4 ml portions were pipetted out into two test tubes. Into one of the test tubes, two drops of eserine solution was added. Then 1 ml of substrate solution (75 mg of acetylthiocholine iodide per 50 ml of distilled water) was pipetted out into both of the test tubes. The test tube containing eserine was taken as blank and the change in absorbance per minute of the test sample was read spectrophotometerically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 420 nm. AChE activity was calculated using the following formula:</p>
<p><disp-formula id="disp-formula1-1470320312459977">
<mml:math display="block" id="math1-1470320312459977">
<mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mfrac>
<mml:mrow>
<mml:mi>δ</mml:mi><mml:mtext>OD</mml:mtext><mml:mo>×</mml:mo><mml:mtext>volume of assay</mml:mtext>
</mml:mrow>
<mml:mrow>
<mml:mtext>E</mml:mtext><mml:mo>×</mml:mo><mml:mtext>mg of protein</mml:mtext>
</mml:mrow>
</mml:mfrac>
</mml:math>
<graphic alternate-form-of="disp-formula1-1470320312459977" xlink:href="10.1177_1470320312459977-eq1.tif"/>
</disp-formula></p>
<p>Where R = rate of enzyme activity in ‘n’ mole of acetylcholine iodide hydrolyzed/min/mg protein</p>
<p>δOD = change in absorbance/min</p>
<p>E = Extinction coefficient = 13600/M/cm</p>
</sec>
<sec id="section10-1470320312459977">
<title>Estimation of brain nitrite/nitrate</title>
<p>Brain nitrite/nitrate concentration in serum nitrite was measured spectophotometrically (DU 640B Spectrophotometer, Beckman Coulter Inc., California, USA) at 542 nm, using the method of Green et al.<sup><xref ref-type="bibr" rid="bibr32-1470320312459977">32</xref></sup> Briefly, 400 µl of carbonate buffer (pH 9.0) was added to 100 µl of supernatant or standards sample followed by addition of small amount (approx. 0.15 g) of copper-cadmium alloy. The tubes were incubated at room temperature for 1 h to reduce nitrate to nitrite. The reaction was stopped by adding 100 µl of 0.35 M sodium hydroxide. Following this, 400 µl of zinc sulfate solution (120 mM) was added to deproteinate the brain homogenate samples. The samples were allowed to stand for 10 min and then centrifuged at 4000 g for 10 min. Greiss reagent (250 µl of 1.0% sulfanilamide prepared in 3N HCl and 250 µl of 0.1% N-naphthylethylenediamine prepared in water) was added to aliquots (500 µl) of clear supernatant and serum nitrite was measured spectophotometrically (DU 640B Spectrophotometer, Beckman Coulter Inc., California, USA) at 542 nm.</p>
</sec>
<sec id="section11-1470320312459977">
<title>Estimation of brain MPO activity</title>
<p>The MPO activity was measured spectrophotometrically (DU 640B Spectrophotometer, Beckman Coulter Inc., California, USA) at 460 nm using the method of Grisham et al.<sup><xref ref-type="bibr" rid="bibr33-1470320312459977">33</xref></sup> Pellets obtained during sample collection were used for estimation of MPO activity. Thus, 10 ml of ice-cold 50 mM potassium phosphate buffer (pH 6.0), containing 0.5% hexadecyl trimethyl ammonium bromide (HETAB) and l0 mM Ethylenediaminetetraacetic acid (EDTA) was added to the pellet. It was then subjected to one cycle of freezing and thawing and a brief period (l5 s) of sonication. After sonication, the solution was centrifuged at 19,000×g for 15 min. The MPO activity was measured spectrophotometrically at 460 nm. One unit of the MPO activity is defined as that which would produce a change in absorbance of 1.0 unit/min at pH 7.0 and 25°C, calculated from the initial rate of reaction with peroxide (1 µM) as the substrate.</p>
</sec>
<sec id="section12-1470320312459977">
<title>Estimation of thiobarbituric acid reactive substances (TBARS)</title>
<p>The quantitative measurement of TBARS, an index of lipid peroxidation in brain was performed according to the method of Ohkawa et al.<sup><xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr29-1470320312459977">29</xref>,<xref ref-type="bibr" rid="bibr34-1470320312459977">34</xref></sup> Thus, 0.2 ml of supernatant of homogenate was pipetted out in a test tube, followed by addition of 0.2 ml of 8.1% sodium dodecyl sulphate, 1.5 ml of 30% acetic acid (pH 3.5), 1.5 ml of 0.8% of thiobarbituric acid and the volume was made up to 4 ml with distilled water. The test tubes were incubated for 1 hr at 95°C, then cooled and 1 ml of distilled water added followed by addition of 5 ml of n-butanol-pyridine mixture (15:1 v/v). The tubes were centrifuged at 4000 g for 10 min. The absorbance of developed pink color was measured spectrophotometrically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 532 nm. A standard calibration curve was prepared using 1–10 nM of 1, 1, 3, 3-tetra methoxy propane.</p>
</sec>
<sec id="section13-1470320312459977">
<title>Estimation of brain GSH</title>
<p>The GSH content in brain was estimated spectrophotometrically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 412 nm using the method of Beutler et al.<sup><xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr29-1470320312459977">29</xref>,<xref ref-type="bibr" rid="bibr35-1470320312459977">35</xref></sup> Briefly, the supernatant of homogenate was mixed with trichloroacetic acid (10% w/v) in 1:1 ratio. The tubes were centrifuged at 1000 g for 10 min at 4°C. The supernatant obtained (0.5 ml) was mixed with 2 ml of 0.3 M disodium hydrogen phosphate. Then 0.25 ml of 0.001 M freshly prepared DTNB dissolved in 1% w/v sodium citrate was added and absorbance was noted spectrophotometrically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 412 nm.</p>
</sec>
<sec id="section14-1470320312459977">
<title>Estimation of brain total protein</title>
<p>The brain total protein was determined by the method of Lowry et al.<sup><xref ref-type="bibr" rid="bibr36-1470320312459977">36</xref></sup> with slight modification.<sup><xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr29-1470320312459977">29</xref></sup> Thus, 0.15 ml of supernatant of tissue homogenate was diluted to 1 ml, then 5 ml of Lowry’s reagent was added. The contents were mixed thoroughly and the mixture was allowed to stand for 15 min at room temperature. Then 0.5 ml of Folin-Ciocalteu reagent was added and the contents were vortexed vigorously and incubated at room temperature for 30 min. The standard curve was plotted using 0.2–2.4 mg/ml of BSA. The protein content was determined spectrophotometrically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 750 nm.</p>
</sec>
<sec id="section15-1470320312459977">
<title>Estimation of serum glucose</title>
<p>The glucose levels were estimated spectrophotometerically (DU 640B spectrophotometer, Beckman Coulter Inc., California, USA) at 505 nm by the glucose oxidase-peroxidase (GOD-POD) method using a commercially available kit (Reckon Diagnostics Pvt. Ltd., Vadodra, India)</p>
</sec>
<sec id="section16-1470320312459977">
<title>Congo red staining as marker of Aβ deposition</title>
<p>Congo red staining was done as per the established method.<sup><xref ref-type="bibr" rid="bibr37-1470320312459977">37</xref></sup> Briefly, mice brains were dissected, and coronal sections were made. The brain samples were fixed in 4% paraformaldehyde for 48 h, and dehydrated in 20% and 30% sucrose, respectively. Tissue sections from the right hemisphere were prepared with the microtome. The sections were dipped in Congo red solution for 18 min, washed in running tap water for 20 min, and then placed in weak alkali for 10 s. The sections were then incubated in hematoxylin for 5 min, washed again in running tap water for 30 min, and de-stained in weak acid for several seconds. The sections were washed again in running water for 15 min, dipped in eosin for 15 s prior to washing again for 20 min, and then dehydrated in an alcohol gradient, followed by xylene clearance and cover slipping. Aβ deposition was observed under a light microscope.</p>
</sec></sec>
<sec id="section17-1470320312459977">
<title>Experimental design</title>
<p>In total, 23 groups were employed in the present study and each group consisted of eight Swiss albino mice. Dosage of the drugs was selected on the basis of previous reports<sup><xref ref-type="bibr" rid="bibr38-1470320312459977">38</xref><xref ref-type="bibr" rid="bibr39-1470320312459977"/><xref ref-type="bibr" rid="bibr40-1470320312459977"/>–<xref ref-type="bibr" rid="bibr41-1470320312459977">41</xref></sup> and on the basis of our pilot studies.</p>
<list id="list2-1470320312459977" list-type="simple"><list-item><p>Group I: Control group</p></list-item></list>
<p>Animals were exposed to the MWM for acquisition trial from Day 1 to Day 4 and retrieval trial on Day 5.</p>
<list id="list3-1470320312459977" list-type="simple"><list-item><p>Group II: Vehicle control group (0.9% saline)</p></list-item></list>
<p>Animals were administered 0.9% saline (10 ml kg<sup>-1</sup> p.o. daily) for 14 days followed by exposure to the MWM. The treatment was continued during acquisition (from 15<sup>th</sup> to 18<sup>th</sup> day) and retrieval trials (on 19<sup>th</sup> day) on the MWM.</p>
<list id="list4-1470320312459977" list-type="simple"><list-item><p>Group III: Vehicle control group (CMC)</p></list-item></list>
<p>Animals were administered 1% sodium carboxymethyl-cellulose (CMC) (10 ml kg<sup>-1</sup> p.o. daily) for 14 days followed by exposure to the MWM. The treatment was continued during acquisition (from 15<sup>th</sup> to 18<sup>th</sup> day) and retrieval trials (on 19<sup>th</sup> day) on the MWM.</p>
<list id="list5-1470320312459977" list-type="simple"><list-item><p>Group IV: Vehicle control group (DMSO)</p></list-item></list>
<p>Animals were administered 0.05% DMSO (10 ml kg<sup>-1</sup> i.p. daily) for 14 days followed by exposure to the MWM. The treatment was continued during acquisition (from 15<sup>th</sup> to 18<sup>th</sup> day) and retrieval trials (on 19<sup>th</sup> day) on the MWM.</p>
<list id="list6-1470320312459977" list-type="simple"><list-item><p>Group V: Vehicle control group (i.c.v. ACSF)</p></list-item></list>
<p>Animals were injected i.c.v. ACSF (25 mg/ml, 5 μl) in two dosage schedules i.e. on first and third day followed by exposure to the MWM after 14 days.</p>
<list id="list7-1470320312459977" list-type="simple"><list-item><p>Group VI: STZ treatment group</p></list-item></list>
<p>Animals were injected i.c.v. STZ (3 mg/kg, 5 μl) in two dosage schedules i.e. on first and third day followed by exposure to the MWM after 14 days.</p>
<list id="list8-1470320312459977" list-type="simple"><list-item><p>Group VII: Lisinopril dose1 per se</p></list-item></list>
<p>Animals were administered lisinopril (10 mg kg<sup>-1</sup> p.o. daily) for 14 days followed by exposure to the MWM. The treatment was continued during acquisition trials (daily 45 min before exposure from 15<sup>th</sup> to 18<sup>th</sup> day). Animals were treated with 1% CMC (10 ml kg<sup>-1</sup> p.o.), 45 min before retrieval trials (on 19<sup>th</sup> day) on the MWM.</p>
<list id="list9-1470320312459977" list-type="simple"><list-item><p>Group VIII: Lisinopril dose2 per se</p></list-item></list>
<p>Animals were administered lisinopril (15 mg kg<sup>-1</sup> p.o. daily) for 14 days and the rest of the procedure was the same as described in Group VII.</p>
<list id="list10-1470320312459977" list-type="simple"><list-item><p>Group IX: STZ and Lisinopril dose1</p></list-item></list>
<p>Lisinopril (10 mg kg<sup>-1</sup> p.o. daily) was administered to the i.c.v. STZ treated mice (starting after the second dose) for 14 days, and the rest of the procedure was the same as described in Group VII.</p>
<list id="list11-1470320312459977" list-type="simple"><list-item><p>Group X: STZ and Lisinopril dose2</p></list-item></list>
<p>Lisinopril (15 mg kg<sup>-1</sup> p.o. daily) was administered to the i.c.v. STZ treated mice (starting after the second dose) for 14 days, and the rest of the procedure was the same as described in Group VII.</p>
<list id="list12-1470320312459977" list-type="simple"><list-item><p>Group XI: Telmisartan dose1 per se</p></list-item></list>
<p>Animals were administered telmisartan (5 mg kg<sup>-1</sup> p.o. daily) for 14 days and the rest of the procedure was the same as described in Group VII.</p>
<list id="list13-1470320312459977" list-type="simple"><list-item><p>Group XII: Telmisartan dose2 per se</p></list-item></list>
<p>Animals were administered telmisartan (10 mg kg<sup>-1</sup> p.o. daily) for 14 days and the rest of the procedure was the same as described in Group VII.</p>
<list id="list14-1470320312459977" list-type="simple"><list-item><p>Group XIII: STZ and telmisartan dose1</p></list-item></list>
<p>Telmisartan (5 mg kg<sup>-1</sup> p.o. daily) was administered to the i.c.v. STZ treated mice (starting after the second dose) for 14 days, and the rest of the procedure was the same as described in Group VII.</p>
<list id="list15-1470320312459977" list-type="simple"><list-item><p>Group XIV: STZ and telmisartan dose2</p></list-item></list>
<p>Telmisartan (10 mg kg<sup>-1</sup> p.o. daily) was administered to the i.c.v. STZ treated mice (starting after the second dose) for 14 days, and the rest of the procedure was the same as described in Group VII.</p>
<list id="list16-1470320312459977" list-type="simple"><list-item><p>Group XV: Donepezil per se</p></list-item></list>
<p>Animals were administered donepezil (0.5 mg kg<sup>-1</sup> p.o. daily) for 14 days followed by exposure to the MWM. The treatment was continued during acquisition trials (daily 45 min before exposure from 15<sup>th</sup> to 18<sup>th</sup> day). Animals were treated with 0.9% saline (10 ml kg<sup>-1</sup> p.o.) 45 min before retrieval trials (on 19<sup>th</sup> day) on the MWM.</p>
<list id="list17-1470320312459977" list-type="simple"><list-item><p>Group XVI: STZ and donepezil</p></list-item></list>
<p>Donepezil (0.5 mg kg<sup>-1</sup> p.o. daily) was administered to the i.c.v. STZ treated mice (starting after the second dose) for 14 days, and the rest of the procedure was the same as described in Group XV.</p>
<list id="list18-1470320312459977" list-type="simple"><list-item><p>Group XVII: Bisphenol-A-diglycidyl ether (BADGE) per se</p></list-item></list>
<p>Mice were administered BADGE (30 mg/kg, i.p. daily, dissolved in DMSO 0.05% w/v + distilled water) for 14 days and treatment was continued during the acquisition trial conducted from day 1 to day 4. The animals were administered vehicle (DMSO 0.05% w/v + distilled water) 30 min before the retrieval trial conducted on day 5 of the MWM test. BADGE was used as a selective inhibitor of PPAR-γ. This was used to see if the selected drugs had any beneficial effect involving PPAR-γ.</p>
<list id="list19-1470320312459977" list-type="simple"><list-item><p>Group XVIII: i.c.v. STZ + BADGE</p></list-item></list>
<p>From the third day onwards (after the second dose of STZ) animals were administered with BADGE for 14 days and then subjected to the MWM test. The treatment was continued during the acquisition trial from day 1 to day 4. The animals were administered the vehicle (DMSO 0.05% w/v + distilled water) 30 min before the retrieval trial conducted on day 5 of the MWM test.</p>
<list id="list20-1470320312459977" list-type="simple"><list-item><p>Group XIX: i.c.v. STZ + BADGE + lisinopril dose1</p></list-item></list>
<p>From the third day onwards (after the second dose of STZ) animals were administered BADGE (30 mg/kg i.p. daily) dissolved in 0.05% DMSO and then lisinopril dose1 after 30 min for 14 days and then subjected to the MWM test. The treatment was continued during the acquisition trial conducted from day 1 to day 4. The animals were administered the vehicle (DMSO 0.05% w/v + distilled water i.p.) 30 min before the retrieval trial conducted on day 5 of the MWM test.</p>
<list id="list21-1470320312459977" list-type="simple"><list-item><p>Group XX: i.c.v. STZ + BADGE + lisinopril dose2</p></list-item></list>
<p>From the third day onwards (after the second dose of STZ) animals were administered BADGE (30 mg/kg i.p. daily) dissolved in 0.05% DMSO and then lisinopril dose2 after 30 min for 14 days and then subjected to the MWM test, and the rest of the procedure was the same for group XIX.</p>
<list id="list22-1470320312459977" list-type="simple"><list-item><p>Group XXI: i.c.v. STZ + BADGE + telmisartan dose1</p></list-item></list>
<p>From the third day onwards (after the second dose of STZ) animals were administered BADGE (30 mg/kg i.p. daily) dissolved in 0.05% DMSO and then telmisartan dose1 after 30 min for 14 days and then subjected to the MWM test, and the rest of the procedure was the same for group XIX.</p>
<list id="list23-1470320312459977" list-type="simple"><list-item><p>Group XXII: i.c.v. STZ + BADGE + telmisartan dose2</p></list-item></list>
<p>From the third day onwards (after the second dose of STZ) animals were administered BADGE (30 mg/kg, i.p. daily) dissolved in 0.05% DMSO and then telmisartan dose2 after 30 min for 14 days and then subjected to the MWM test, and the rest of the procedure was the same for group XIX.</p>
<list id="list24-1470320312459977" list-type="simple"><list-item><p>Group XXIII: i.c.v. STZ + BADGE + donepezil</p></list-item></list>
<p>From the third day onwards (after the second dose of STZ) animals were administered BADGE (30 mg/kg, i.p. daily) dissolved in 0.05% DMSO and then donepezil after 30 min for 14 days and then subjected to the MWM test, and the rest of the procedure was the same for group XIX.</p>
</sec>
<sec id="section18-1470320312459977">
<title>Statistical analysis</title>
<p>The observations were statistically analyzed with the help of Sigmastat software version 3.5. All of the results were expressed as mean±standard error of the mean (SEM). Results were analyzed using one-way analysis of variance (ANOVA), followed by Tukey’s multiple range test and <italic>p</italic>&lt;0.05 was considered to be statistically significant.</p>
</sec></sec>
<sec id="section19-1470320312459977" sec-type="results">
<title>Results</title>
<sec id="section20-1470320312459977">
<title>Effect on ELT and time spent in target quadrant (TSTQ) using the MWM</title>
<p>Control mice showed a downward trend in their ELT. There was a significant fall in day 4 ELT when compared to day 1 ELT of these mice (<xref ref-type="table" rid="table1-1470320312459977">Table 1</xref>) reflecting normal learning ability. Further, on day 5 a significant rise in TSTQ was observed when compared to time spent in other quadrants (<xref ref-type="fig" rid="fig1-1470320312459977">Figure 1</xref>), reflecting normal retrieval as well. Administration of 0.9% saline (10 ml kg<sup>-1</sup> p.o. 18 days)/CMC (10 ml kg<sup>-1</sup> p.o. 18 days)/ACSF (25 mg/ml, 5 μl, two doses) did not show any significant effect on ELT and TSTQ as compared to control mice. Administration of lisinopril (10 mg kg<sup>-1</sup> p.o./15 mg kg<sup>-1</sup> p.o. 18 days)/telmisartan (5 mg kg<sup>-1</sup> p.o./10 mg kg<sup>-1</sup> p.o. 18 days)/donepezil (0.5 mg kg<sup>-1</sup> i.p. 18 days) did not show any significant per se effect on ELT and TSTQ. (<xref ref-type="table" rid="table1-1470320312459977">Table 1</xref> and <xref ref-type="fig" rid="fig1-1470320312459977">Figure 1</xref>). STZ (3 mg kg<sup>-1</sup> i.c.v., two doses) treated mice showed a significant increase in day 4 ELT (18<sup>th</sup> day from second dose treatment of STZ), when compared to day 4 ELT of control animals (<xref ref-type="table" rid="table1-1470320312459977">Table 1</xref>) indicating impairment of acquisition. Further STZ administration also produced a significant decrease in day 5 TSTQ (19<sup>th</sup> day from the last dose of STZ), when compared to day 5 TSTQ of control animals (<xref ref-type="fig" rid="fig1-1470320312459977">Figure 1</xref>), indicating impairment of memory as well.</p>
<table-wrap id="table1-1470320312459977" position="float">
<label>Table 1.</label>
<caption>
<p>Reversal of streptozotocin (STZ) intracerebroventricular (i.c.v.) induced increase in Day 4 escape latency time (ELT) by lisinopril, telmisartan and donepezil</p>
</caption>
<graphic alternate-form-of="table1-1470320312459977" xlink:href="10.1177_1470320312459977-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Group</th>
<th align="left">Group name</th>
<th align="left">Day 1 ELT (in s)</th>
<th align="left">Day 4 ELT (in s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Control</td>
<td>114±6</td>
<td>48±4<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>II</td>
<td>0.9% saline</td>
<td>112±7</td>
<td>50±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>III</td>
<td>1% CMC</td>
<td>115±4</td>
<td>49±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>IV</td>
<td>DMSO</td>
<td>112±2</td>
<td>51±3<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>V</td>
<td>ACSF</td>
<td>116±3</td>
<td>53±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>VI</td>
<td>STZ</td>
<td>113±6</td>
<td>87±7<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">b</xref></sup></td>
</tr>
<tr>
<td>VII</td>
<td>Lis D1 per se</td>
<td>114±4</td>
<td>51±5<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>VIII</td>
<td>Lis D2 per se</td>
<td>112±5</td>
<td>50±3<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>IX</td>
<td>STZ &amp; Lis D1</td>
<td>116±3</td>
<td>72±5<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">c</xref></sup></td>
</tr>
<tr>
<td>X</td>
<td>STZ &amp; Lis D2</td>
<td>118±2</td>
<td>68±4<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">c</xref></sup></td>
</tr>
<tr>
<td>XI</td>
<td>Telm D1 per se</td>
<td>110±4</td>
<td>52±3<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>XII</td>
<td>Telm D2 per se</td>
<td>108±5</td>
<td>49±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>XIII</td>
<td>STZ &amp; Telm D1</td>
<td>114±4</td>
<td>69±5<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">c</xref></sup></td>
</tr>
<tr>
<td>XIV</td>
<td>STZ &amp; Telm D2</td>
<td>112±5</td>
<td>66±4<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">c</xref></sup></td>
</tr>
<tr>
<td>XV</td>
<td>Don per se</td>
<td>104±4</td>
<td>48±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>XVI</td>
<td>STZ &amp; Don</td>
<td>109±5</td>
<td>60±3<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">c</xref></sup></td>
</tr>
<tr>
<td>XVII</td>
<td>BADGE per se</td>
<td>108±6</td>
<td>46±7<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref></sup></td>
</tr>
<tr>
<td>XVIII</td>
<td>STZ+BADGE</td>
<td>112±8</td>
<td>85±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">b</xref></sup></td>
</tr>
<tr>
<td>XIX</td>
<td>STZ+BADGE+Lis D1</td>
<td>114±3</td>
<td>79±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">d</xref></sup></td>
</tr>
<tr>
<td>XX</td>
<td>STZ+BADGE+Lis D2</td>
<td>116±4</td>
<td>76±4<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">d</xref></sup></td>
</tr>
<tr>
<td>XXI</td>
<td>STZ+BADGE+Telm D1</td>
<td>111±2</td>
<td>81±6<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">d</xref></sup></td>
</tr>
<tr>
<td>XXII</td>
<td>STZ+BADGE+Telm D2</td>
<td>109±6</td>
<td>78±7<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">d</xref></sup></td>
</tr>
<tr>
<td>XXIII</td>
<td>STZ+BADGE+Don</td>
<td>108±9</td>
<td>53±4<sup><xref ref-type="table-fn" rid="table-fn3-1470320312459977">a</xref>,<xref ref-type="table-fn" rid="table-fn3-1470320312459977">c</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320312459977"><p>ACSF: artificial cerebrospinal fluid; BADGE: bisphenol-A-diglycidyl ether; CMC: sodium carboxy methyl cellulose; D1: dose1; D2: dose2; DMSO: dimethylsulfoxide; Don: donepezil; Lis: lisinopril; Telm: telmisartan.</p></fn>
<fn id="table-fn2-1470320312459977"><p>For all groups <italic>n</italic>=8, all the data for ELT are represented as mean±standard error of the mean (SEM), and were statistically analyzed using one way analysis of variance (ANOVA) followed by Tukey’s multiple range test.</p></fn>
<fn id="table-fn3-1470320312459977">
<label>a</label>
<p><italic>p</italic>&lt;0.05 versus day 1 ELT time in respective groups; <sup>b</sup><italic>p</italic>&lt;0.05 versus day 4 ELT in control group; <sup>c</sup><italic>p</italic>&lt;0.05 versus day 4 ELT in STZ treated group; <sup>d</sup><italic>p</italic>&lt;0.05 versus day 4 ELT in respective drug + STZ treated group.</p></fn>
</table-wrap-foot></table-wrap>
<fig id="fig1-1470320312459977" position="float">
<label>Figure 1.</label>
<caption>
<p>Per se effect of drugs on mean time spent in target quadrant (TSTQ) using the Morris water maze.</p>
<p>CMC: sodium carboxy methyl cellulose; DMSO: dimethylsulfoxide; ACSF: artificial cerebrospinal fluid; STZ: streptozotocin; Lis: lisinopril; Telm: telmisartan; Don: donepezil; BADGE: bisphenol-A-diglycidyl ether; D1: dose1; D2: dose2.</p>
<p>For all groups <italic>n</italic>=8, all the data for TSTQ are represented as mean±standard error of the mean (SEM) and were statistically analyzed using one way analysis of variance (ANOVA) followed by Tukey’s multiple range test.</p>
<p><sup><bold>a</bold></sup><italic>p</italic>&lt;0.05 versus mean time spent in other quadrants in control group.</p>
<p><sup><bold>b</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in control group.</p>
</caption>
<graphic xlink:href="10.1177_1470320312459977-fig1.tif"/></fig>
<p>Administration of lisinopril (dose1 as well as dose2)/telmisartan (dose1 as well as dose2)/donepezil, significantly prevented an STZ induced rise in day 4 ELT, indicating reversal of STZ induced impairment of acquisition (<xref ref-type="table" rid="table1-1470320312459977">Table 1</xref>). Further treatment with these drugs also attenuated the STZ induced decrease in day 5 TSTQ in a significant manner, indicating reversal of STZ induced impairment of memory (<xref ref-type="fig" rid="fig2-1470320312459977">Figures 2</xref> and <xref ref-type="fig" rid="fig3-1470320312459977">3</xref>). BADGE (30 mg/kg, i.p.) significantly reversed the beneficial efect of lisinopril (dose1 as well as dose2)/telmisartan (dose1 as well as dose2) in STZ treated animals without effecting the beneficial effect of donepezil (<xref ref-type="fig" rid="fig2-1470320312459977">Figures 2</xref> and <xref ref-type="fig" rid="fig3-1470320312459977">3</xref>). BADGE has neither shown any significant per se effect nor any effect in STZ alone treated animals (<xref ref-type="fig" rid="fig1-1470320312459977">Figures 1</xref>, <xref ref-type="fig" rid="fig2-1470320312459977">2</xref> and <xref ref-type="fig" rid="fig3-1470320312459977">3</xref>).</p>
<fig id="fig2-1470320312459977" position="float">
<label>Figure 2.</label>
<caption>
<p>Effect of lisinopril on mean time spent in target quadrant (TSTQ) using the Morris water maze.</p>
<p>BADGE: bisphenol-A-diglycidyl ether; D1: dose1; D2: dose2; Don: donepezil; Lis: lisinopril; STZ: streptozotocin.</p>
<p>For all groups <italic>n</italic>=8, all the data for TSTQ is represented as mean±standard error of the mean (SEM) and was statistically analyzed using one way analysis of variance (ANOVA) followed by Tukey’s multiple range test.</p>
<p><sup><bold>a</bold></sup><italic>p</italic>&lt;0.05 versus mean time spent in other quadrants in control group.</p>
<p><sup><bold>b</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in control group.</p>
<p><sup><bold>c</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in STZ treated group.</p>
<p><sup><bold>d</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in STZ + Lis (D1) treated group.</p>
<p><sup><bold>e</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in STZ + Lis (D2) treated group.</p>
</caption>
<graphic xlink:href="10.1177_1470320312459977-fig2.tif"/></fig>
<fig id="fig3-1470320312459977" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of telmisartan on mean time spent in target quadrant (TSTQ) using the Morris water maze.</p>
<p>BADGE: bisphenol-A-diglycidyl ether; D1: dose1; D2: dose2; Don: donepezil; STZ: streptozotocin. Telm: telmisartan.</p>
<p>For all groups <italic>n</italic>=8, all the data for TSTQ are represented as mean±standard error of the mean (SEM) and were statistically analyzed using one way analysis of variance (ANOVA) followed by Tukey’s multiple range test.</p>
<p><sup><bold>a</bold></sup><italic>p</italic>&lt;0.05 versus mean time spent in other quadrants in control group.</p>
<p><sup><bold>b</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in control group.</p>
<p><sup><bold>c</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in STZ treated group.</p>
<p><sup><bold>d</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in STZ + Telm (D1) treated group.</p>
<p><sup><bold>e</bold></sup><italic>p</italic>&lt;0.05 versus mean TSTQ in STZ + Telm (D2) treated group.</p>
</caption>
<graphic xlink:href="10.1177_1470320312459977-fig3.tif"/></fig>
</sec>
<sec id="section21-1470320312459977">
<title>Effect on various biochemical parameters</title>
<p>Administration of i.c.v. STZ/lisinopril (dose1 as well as dose2)/telmisartan (dose1 as well as dose2)/donepezil, did not produce any significant effect on the serum glucose levels of treated animals, when compared to control animals (<xref ref-type="table" rid="table2-1470320312459977">Table 2</xref>). Administration of i.c.v. STZ produced a significant increase in brain MPO activity, AChE activity, nitrite/nitrate and TBARS levels along with decrease in brain GSH, when compared to control rats. Treatment with lisinopril (dose1 as well as dose2)/telmisartan (dose1 as well as dose2)/donepezil significantly prevented i.c.v. STZ induced increases in brain MPO, AChE, nitrate/nitrite, TBARS levels and a decrease in brain GSH levels (<xref ref-type="table" rid="table2-1470320312459977">Table 2</xref>). BADGE significantly reversed the beneficial efect of lisinopril (dose1 as well as dose2)/telmisartan (dose1 as well as dose2) in STZ treated animals without affecting the beneficial effect of donepezil. BADGE showed neither any significant per se effect nor any effect in STZ alone treated animals.</p>
<table-wrap id="table2-1470320312459977" position="float">
<label>Table 2.</label>
<caption>
<p>Effect of different treatments on various biochemical parameters</p>
</caption>
<graphic alternate-form-of="table2-1470320312459977" xlink:href="10.1177_1470320312459977-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Group</th>
<th align="left">Group name</th>
<th align="left" colspan="2">Serum glucose (mg/dl)<hr/></th>
<th align="left">Brain AChE activity (nM/min/mg of protein)</th>
<th align="left">Brain nitrite/nitrate (µg/mg protein)</th>
<th align="left">Brain MPO activity (U/g of protein)</th>
<th align="left">Brain TBARS (nM/mg protein)</th>
<th align="left">Brain GSH (nM/mg protein)</th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Basal</th>
<th align="left">Final</th>
<th/>
<th/>
<th/>
<th/>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Control</td>
<td>102.3±2.5</td>
<td>101.4±4.5</td>
<td>121.2±10.4</td>
<td>10.6±2.2</td>
<td>0.023±0.004</td>
<td>19.2±3.4</td>
<td>32.1±4.5</td>
</tr>
<tr>
<td>II</td>
<td>0.9% saline</td>
<td>104.2±3.1</td>
<td>105.3±2.2</td>
<td>123.3±13.3</td>
<td>11.1±1.3</td>
<td>0.026±0.003</td>
<td>20.1±3.6</td>
<td>30.4±3.6</td>
</tr>
<tr>
<td>III</td>
<td>1% CMC</td>
<td>101.3±3.3</td>
<td>104.1±2.8</td>
<td>119.4±9.4</td>
<td>10.2±3.1</td>
<td>0.021±0.004</td>
<td>19.7±2.8</td>
<td>31.3±4.1</td>
</tr>
<tr>
<td>IV</td>
<td>DMSO</td>
<td>103.4±2.2</td>
<td>104.6±2.3</td>
<td>120.8±4.1</td>
<td>10.3±7.6</td>
<td>0.025±0.004</td>
<td>19.4±3.7</td>
<td>30.8±2.5</td>
</tr>
<tr>
<td>V</td>
<td>ACSF</td>
<td>99.2±4.2</td>
<td>103.1±2.1</td>
<td>120.5±16.2</td>
<td>11.4±2.1</td>
<td>0.019±0.002</td>
<td>21.3±3.9</td>
<td>32.6±3.2</td>
</tr>
<tr>
<td>VI</td>
<td>STZ</td>
<td>101.9±2.2</td>
<td>102.8±3.2</td>
<td>258.3±22.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>38.9±4.3<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>0.145±0.023<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>91.2±7.8<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>12.2±2.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
</tr>
<tr>
<td>VII</td>
<td>Lis D1 per se</td>
<td>99.8±3.2</td>
<td>97.6±4.3</td>
<td>123.5±14.3</td>
<td>10.1±2.1</td>
<td>0.022±0.005</td>
<td>18.9±2.4</td>
<td>31.3±3.7</td>
</tr>
<tr>
<td>VIII</td>
<td>Lis D2 per se</td>
<td>103.4±3.3</td>
<td>101.6±3.8</td>
<td>120.3±18.2</td>
<td>10.4±1.9</td>
<td>0.019±0.003</td>
<td>19.3±2.2</td>
<td>32.4±3.2</td>
</tr>
<tr>
<td>IX</td>
<td>STZ &amp; Lis D1</td>
<td>102.4±4.1</td>
<td>104.2±4.4</td>
<td>198.3±16.9<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>26.2±2.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>0.124±0.014<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>61.4±2.8<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>20.2±2.3<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
</tr>
<tr>
<td>X</td>
<td>STZ &amp; Lis D2</td>
<td>105.2±3.5</td>
<td>103.6±4.2</td>
<td>187.9±14.9<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>23.4±2.4<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>0.115±0.021<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>54.2±3.8<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>21.3±3.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
</tr>
<tr>
<td>XI</td>
<td>Telm D1 per se</td>
<td>104.5±4.2</td>
<td>102.2±3.8</td>
<td>120.8±12.6</td>
<td>11.2±1.7</td>
<td>0.024±0.006</td>
<td>19.2±2.9</td>
<td>30.4±3.7</td>
</tr>
<tr>
<td>XII</td>
<td>Telm D2 per se</td>
<td>102.4±2.9</td>
<td>105.1±4.2</td>
<td>124.4±16.3</td>
<td>10.7±2.4</td>
<td>0.021±0.003</td>
<td>20.5±3.2</td>
<td>31.2±3.9</td>
</tr>
<tr>
<td>XIII</td>
<td>STZ &amp; Telm D1</td>
<td>103.2±3.1</td>
<td>105.3±2.3</td>
<td>201.2±20.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>24.2±2.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>0.112±0.009<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>52.3±3.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>23.2±2.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
</tr>
<tr>
<td>XIV</td>
<td>STZ &amp; Telm D2</td>
<td>101.3±2.3</td>
<td>104.1±3.3</td>
<td>193.4±21.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>21.4±2.3<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>0.103±0.012<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>48.2±4.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>25.7±3.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
</tr>
<tr>
<td>XV</td>
<td>Don per se</td>
<td>103.2±4.3</td>
<td>102.2±3.8</td>
<td>120.4±20.3</td>
<td>10.9±2.4</td>
<td>0.022±0.005</td>
<td>21.1±1.6</td>
<td>32.6±2.1</td>
</tr>
<tr>
<td>XVI</td>
<td>STZ &amp; Don</td>
<td>104.3±1.9</td>
<td>102.5±3.4</td>
<td>160.2±12.3<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>25.4±2.7<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>0.096±0.015<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>39.2±2.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>24.8±2.4<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
</tr>
<tr>
<td>XVII</td>
<td>BADGE per se</td>
<td>102.3±4.5</td>
<td>103.4±3.1</td>
<td>128.6±11.3</td>
<td>11.4±5.1</td>
<td>0.024±0.002</td>
<td>19.6±3.7</td>
<td>31.4±2.2</td>
</tr>
<tr>
<td>XVIII</td>
<td>STZ+BADGE</td>
<td>101.3±4.2</td>
<td>102.7±1.1</td>
<td>124.2±14.4<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>37.6±2.6<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>0.142±0.032<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>87.9±4.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
<td>14.3±2.3<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">a</xref></bold></sup></td>
</tr>
<tr>
<td>XIX</td>
<td>STZ+BADGE+Lis D1</td>
<td>102.5±3.6</td>
<td>104.8±4.4</td>
<td>237.5±11.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>31.2±2.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>0.133±0.012<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>79.6±2.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>15.5±3.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
</tr>
<tr>
<td>XX</td>
<td>STZ+BADGE+Lis D2</td>
<td>104.1±3.3</td>
<td>105.4±3.1</td>
<td>232.4±14.6<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>29.4±3.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>0.129±0.018<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>82.2±4.8<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>19.6±2.7<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
</tr>
<tr>
<td>XXI</td>
<td>STZ+BADGE+ Telm D1</td>
<td>103.5±4.7</td>
<td>104.2±3.3</td>
<td>248.4±18.3<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>34.5±4.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>0.124±0.012<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>83.5±3.6<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>18.4±3.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
</tr>
<tr>
<td>XXII</td>
<td>STZ+BADGE+ Telm D2</td>
<td>101.7±3.6</td>
<td>102.4±3.1</td>
<td>242.7±14.6<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>31.4±6.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>0.121±0.024<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>81.2±4.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
<td>19.6±6.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">c</xref></bold></sup></td>
</tr>
<tr>
<td>XXIII</td>
<td>STZ+BADGE+Don</td>
<td>103.4±4.1</td>
<td>104.7±2.6</td>
<td>165.2±12.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>23.6±4.2<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>0.099±0.014<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>42.8±2.1<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
<td>25.6±3.5<sup><bold><xref ref-type="table-fn" rid="table-fn6-1470320312459977">b</xref></bold></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1470320312459977"><p>AChE: acetylcholinesterase; ACSF: artificial cerebrospinal fluid; BADGE: bisphenol-A-diglycidyl ether; CMC: sodium carboxy methyl cellulose; D1: dose1; D2: dose2; DMSO: dimethylsulfoxide; Don: donepezil; GSH: reduced glutathione; Lis: lisinopril; MPO: myeloperoxidase; STZ: streptozotocin; TBARS: thiobarbituric acid reactive species; Telm: telmisartan.</p></fn>
<fn id="table-fn5-1470320312459977"><p>For all groups <italic>n</italic>=8, all the data are represented as mean±standard error of the mean (SEM) and were statistically analyzed using one way analysis of variance (ANOVA) followed by Tukey’s multiple range test.</p></fn>
<fn id="table-fn6-1470320312459977">
<label>a</label>
<p><italic>p</italic>&lt;0.05 versus control group; <sup>b</sup><italic>p</italic>&lt;0.05 versus STZ (i.c.v.) treated group; <sup>c</sup><italic>p</italic>&lt;0.05 versus respective drug + STZ treated group.</p></fn>
</table-wrap-foot></table-wrap>
<p>Further, lisinopril (dose1 as well as dose2)/telmisartan (dose1 as well as dose2)/donepezil did not show any significant per se effect on any of the biochemical parameters (<xref ref-type="table" rid="table2-1470320312459977">Table 2</xref>).</p>
</sec>
<sec id="section22-1470320312459977">
<title>Effect on Congo red staining</title>
<p>Histopathological slides of mice brain-coronal sections were observed for the presence of Aβ deposits. Control group animals did not show any Congo red staining (<xref ref-type="fig" rid="fig4-1470320312459977">Figure 4(A)</xref>). Administration of i.c.v. STZ (3 mg/kg, 5 µl on the first and third day) showed significant Congo red staining when compared to control animals (<xref ref-type="fig" rid="fig4-1470320312459977">Figure 4(B)</xref>). Treatment with telmisartan (dose2)/lisinopril (dose2) significantly reduced i.c.v. STZ induced Congo red staining (<xref ref-type="fig" rid="fig4-1470320312459977">Figures 4(C)</xref> and <xref ref-type="fig" rid="fig4-1470320312459977">4(E)</xref>). Further pretreatment of BADGE abolished the preventive effect of lisinopril and telmisartan in i.c.v. STZ induced histopathological changes (<xref ref-type="fig" rid="fig4-1470320312459977">Figures 4(D)</xref> and <xref ref-type="fig" rid="fig4-1470320312459977">4(F)</xref>).</p>
<fig id="fig4-1470320312459977" position="float">
<label>Figure 4.</label>
<caption>
<p>Effect of telmisartan and lisinopril on i.c.v. streptozotocin (STZ) induced histopathological changes in mice brain coronal sections.</p>
<p>(A) Control; (B) i.c.v. STZ; (C) i.c.v. STZ + telmisartan; (D) i.c.v. STZ + BADGE + telmisartan; (E) i.c.v. STZ + lisinopril; (F) i.c.v. STZ + BADGE + lisinopril.</p>
<p>Light microscope ×100, arrow shows Congo red stained area as a marker of amyloid-β (Aβ) deposits.</p>
</caption>
<graphic xlink:href="10.1177_1470320312459977-fig4.tif"/></fig>
<p>BADGE was used as the selective inhibitor of PPAR-γ BADGE reversed the beneficial effect of both lisinopril as well as telmisartan in i.c.v. STZ treated animals. Administration of both of these drugs to BADGE pre-treated animals did not show any beneficial effect on i.c.v. STZ induced learning and memory impairment and various biochemical alterations. Thus, there is the possibility that these drugs act through PPAR-γ receptors.</p>
</sec></sec>
<sec id="section23-1470320312459977" sec-type="discussion">
<title>Discussion</title>
<p>The MWM employed in the present study is one of the most accepted models to evaluate the learning and memory of rodents.<sup><xref ref-type="bibr" rid="bibr28-1470320312459977">28</xref>,<xref ref-type="bibr" rid="bibr42-1470320312459977">42</xref></sup> Control untreated animals in this study showed a marked reduction in day 4 ELT as compared to day 1 ELT during the acquisition trial, suggesting normal acquisition or learning ability. Further, these animals have shown a significant increase in day 5 mean TSTQ when compared to time spent in other quadrants, indicating normal retrieval (memory) as well. These results are in line with previous studies from our own laboratory<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr29-1470320312459977">29</xref></sup> as well as from other laboratories.<sup><xref ref-type="bibr" rid="bibr43-1470320312459977">43</xref>,<xref ref-type="bibr" rid="bibr44-1470320312459977">44</xref></sup></p>
<p>Administration of i.c.v. STZ resulted in impairment of learning and memory in mice as indicated by a significant increase in day 4 ELT and decrease in day 5 TSTQ. Moreover i.c.v. STZ treated animals showed a significant increase in brain MPO activity, AChE activity, nitrite/nitrate levels and TBARS levels along with depletion of brain GSH levels. These findings are also in line with previous studies.<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr41-1470320312459977">41</xref>,<xref ref-type="bibr" rid="bibr45-1470320312459977">45</xref></sup> Moreover, marked histopathological changes were also noted in the i.c.v. STZ treated mice. The i.c.v. STZ model has been described as an appropriate animal model for AD, typically characterized by progressive impairment of learning abilities and memory capacities.<sup><xref ref-type="bibr" rid="bibr46-1470320312459977">46</xref></sup> The i.c.v. STZ induced memory loss is independent of its hyperglycemic effect.<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr47-1470320312459977">47</xref></sup> The i.c.v. STZ in rats causes desensitization of insulin receptors (IRs) and biochemical changes similar to that of AD or the ageing brain.<sup><xref ref-type="bibr" rid="bibr48-1470320312459977">48</xref><xref ref-type="bibr" rid="bibr49-1470320312459977"/>–<xref ref-type="bibr" rid="bibr50-1470320312459977">50</xref></sup> Brain insulin controls the breakdown of glucose via IRs in the brain and yields acetyl coenzyme A (acetyl CoA), glutamate and Adenosine triphosphate (ATP) which are required for normal structure and function of neurons.<sup><xref ref-type="bibr" rid="bibr51-1470320312459977">51</xref></sup> Acetyl CoA is a main constituent of neurotransmitter acetylcholine synthesis and plays a vital role in the learning and memory processes. Brain IRs are reported to be associated with memory functions and may get affected by oxidative stress in STZ induced dementia.<sup><xref ref-type="bibr" rid="bibr51-1470320312459977">51</xref></sup> Oxidative stress caused by i.c.v. STZ, damages the myelin.<sup><xref ref-type="bibr" rid="bibr52-1470320312459977">52</xref></sup> Further it has been reported that i.c.v. STZ causes an increase in brain inflammation by upregulation of some genes of the brain namely those encoding brain-derived neurotrophic factor, glial cell derived neurotrophic factor and integrin-alpha-M.<sup><xref ref-type="bibr" rid="bibr53-1470320312459977">53</xref></sup> Furthermore, i.c.v. STZ also induces upregulation of Inducible nitric oxide synthase (iNOS) and concomitant increase in oxidative stress leading to the formation of peroxynitrite, a powerful pro-oxidant.<sup><xref ref-type="bibr" rid="bibr54-1470320312459977">54</xref>,<xref ref-type="bibr" rid="bibr55-1470320312459977">55</xref></sup></p>
<p>In this study the administration of lisinopril (an ACEI), telmisartan (an ARB), as well as donepezil (an AChEI), significantly reduced the negative effects of i.c.v. STZ on the learning and memory of mice. These drugs also attenuated i.c.v. STZ induced increases in brain MPO, AChE, nitrite/nitrate, TBARS levels as well as a decrease in brain GSH. Moreover i.c.v. STZ induced histopathological changes were also arrested.</p>
<p>The RAS has been implicated in the pathogenesis of hypertension and related cardiovascular disease. Several components of the RAS, namely angiotensinogen, angiotensin converting enzyme, angiotensin II and their receptors have been found in the CNS suggesting the possibility of a localized RAS in the brain. The RAS in the CNS may contribute to the disease process of CNS disorders including AD, probably through neuronal death and memory dysfunctions.<sup><xref ref-type="bibr" rid="bibr9-1470320312459977">9</xref>,<xref ref-type="bibr" rid="bibr56-1470320312459977">56</xref>,<xref ref-type="bibr" rid="bibr57-1470320312459977">57</xref></sup> High levels of angiotensin II are reported to contribute to oxidative stress<sup><xref ref-type="bibr" rid="bibr58-1470320312459977">58</xref></sup> and inflammation<sup><xref ref-type="bibr" rid="bibr59-1470320312459977">59</xref></sup> which produce deleterious effects in the CNS. It has been noted that ACEIs may provide benefits in cognition beyond blood pressure control.<sup><xref ref-type="bibr" rid="bibr60-1470320312459977">60</xref></sup> High levels of angiotensin II have also been shown to inhibit acetylcholine release in rats and humans.<sup><xref ref-type="bibr" rid="bibr61-1470320312459977">61</xref>,<xref ref-type="bibr" rid="bibr62-1470320312459977">62</xref></sup> Hence, it may be considered that ACEIs and ARBs decrease the effect of the angiotensin II which may reduce the inhibitory action on acetylcholine release and thereby increase acetylcholine concentration. It has been demonstrated that stimulation of the RAS causes activation of inflammatory cytokines that may play a vital role in degenerative dementias.<sup><xref ref-type="bibr" rid="bibr63-1470320312459977">63</xref>,<xref ref-type="bibr" rid="bibr64-1470320312459977">64</xref></sup></p>
<p>ACEIs like lisinopril and ARBs like telmisartan have been reported in recent studies to possess anti-inflammatory actions.<sup><xref ref-type="bibr" rid="bibr65-1470320312459977">65</xref><xref ref-type="bibr" rid="bibr66-1470320312459977"/><xref ref-type="bibr" rid="bibr67-1470320312459977"/>–<xref ref-type="bibr" rid="bibr68-1470320312459977">68</xref></sup> Clinical exposure to ACEIs that do cross the blood brain barrier (BBB) have been found to be associated with a significant reduction in cognitive decline as compared to those ACEIs which do not cross the BBB.<sup><xref ref-type="bibr" rid="bibr60-1470320312459977">60</xref>,<xref ref-type="bibr" rid="bibr69-1470320312459977">69</xref></sup> Lisinopril has been reported for its easy entry in the brain through the BBB and it can cause marked inhibition of brain ACE by its central action.<sup><xref ref-type="bibr" rid="bibr60-1470320312459977">60</xref>,<xref ref-type="bibr" rid="bibr70-1470320312459977">70</xref></sup> A recent report suggests that lisinopril is associated with reductions in the incidence and progression of AD dementia in cardiovascular patients.<sup><xref ref-type="bibr" rid="bibr10-1470320312459977">10</xref></sup> ACEIs have also been reported to attenuate age-related impairment in learning and memory in normotensive rats.<sup><xref ref-type="bibr" rid="bibr71-1470320312459977">71</xref></sup> Alteration of i.c.v. STZ induced dementia by lisinopril in our study further substantiates the above findings and implies that ACEIs may have potential for use in dementia of AD and other types. Interestingly, a study says that inhibition of brain ACE may result in enhancement of Aβ1–40 deposition and can increase the risk of AD.<sup><xref ref-type="bibr" rid="bibr14-1470320312459977">14</xref></sup> However, it was demonstrated that short term treatment of ACEIs failed to increase brain Aβ formation but long-term treatment enhanced Aβ1–42 deposition in aged amyloid precursor protein (APP) transgenic mice.<sup><xref ref-type="bibr" rid="bibr14-1470320312459977">14</xref></sup> Recently it has been reported that telmisartan shows cerebroprotective effects,<sup><xref ref-type="bibr" rid="bibr72-1470320312459977">72</xref></sup> improves cognitive decline in AD,<sup><xref ref-type="bibr" rid="bibr38-1470320312459977">38</xref></sup> provides neuroprotection<sup><xref ref-type="bibr" rid="bibr73-1470320312459977">73</xref>,<xref ref-type="bibr" rid="bibr74-1470320312459977">74</xref></sup> and these actions of telmisartan are attributed to its potential anti-oxidative,<sup><xref ref-type="bibr" rid="bibr75-1470320312459977">75</xref></sup> anti-inflammatory, <sup><xref ref-type="bibr" rid="bibr65-1470320312459977">65</xref>,<xref ref-type="bibr" rid="bibr67-1470320312459977">67</xref>,<xref ref-type="bibr" rid="bibr68-1470320312459977">68</xref></sup> anti-cholinesterase<sup><xref ref-type="bibr" rid="bibr76-1470320312459977">76</xref></sup> and anti-Aβ<sup><xref ref-type="bibr" rid="bibr38-1470320312459977">38</xref></sup> effects. Consistent with these reports, lisinopril, as well as telmisartan, has also exhibited beneficial effects in i.c.v. STZ induced dementia. Further, it has been reported that ARBs as well as ACEIs are associated with a significant reduction in the incidence and progression of AD and dementia in a predominantly male population.<sup><xref ref-type="bibr" rid="bibr10-1470320312459977">10</xref></sup> The antihypertensives and vascular, endothelial and cognitive function (AVEC) trial in elderly hypertensive patients with early cognitive impairment is studying the effect of ARBs and ACEIs in memory impairment: the results of this trial are still awaited but success of this trial will offer a new therapeutic application of antihypertensives that inhibit the RAS and new insights into the role of this system in aging including dementia.<sup><xref ref-type="bibr" rid="bibr77-1470320312459977">77</xref></sup> On the other hand, data analysis from the ONTARGET and TRANSCEND studies suggests that, in cardiovascular disease or diabetes, different approaches to blocking of the RAS had no clear effects on cognitive outcomes. Although patients with the lowest systolic blood pressure had the greatest preservation of cognitive function, meta-regression analyses did not show any benefits of lowering blood pressure on cognition over several years of treatment.<sup><xref ref-type="bibr" rid="bibr78-1470320312459977">78</xref></sup> An ARB has also been reported to have had a preventive effect on cognitive impairment in AD in ddY mice.<sup><xref ref-type="bibr" rid="bibr39-1470320312459977">39</xref></sup></p>
<p>In this investigation, pretreatment with BADGE, a selective PPAR-γ antagonist, has reversed the beneficial effects of lisinopril and telemisartan on impairment of learning, memory and altered biochemical parameters of i.c.v. STZ animals. Previous studies have documented the PPAR-γ agonistic activity of lisinopril as well as telmisartan.<sup><xref ref-type="bibr" rid="bibr26-1470320312459977">26</xref>,<xref ref-type="bibr" rid="bibr27-1470320312459977">27</xref></sup> PPAR-γ is expressed widely in the CNS where it has a prominent role in the regulation of neuroprotection.<sup><xref ref-type="bibr" rid="bibr79-1470320312459977">79</xref>,<xref ref-type="bibr" rid="bibr80-1470320312459977">80</xref></sup> PPAR-γ agonists have been shown to exert neuroprotective effect in ischemia and intracerebral hemorrhage.<sup><xref ref-type="bibr" rid="bibr79-1470320312459977">79</xref>,<xref ref-type="bibr" rid="bibr81-1470320312459977">81</xref>,<xref ref-type="bibr" rid="bibr82-1470320312459977">82</xref></sup> Further, an increase in susceptibility to brain damage after cerebral ischemia associated with deficiency of neuronal PPAR-γ has been reported.<sup><xref ref-type="bibr" rid="bibr80-1470320312459977">80</xref>,<xref ref-type="bibr" rid="bibr83-1470320312459977">83</xref></sup> PPAR-γ agonists have also been found to have excellent antioxidant activity.<sup><xref ref-type="bibr" rid="bibr10-1470320312459977">10</xref>,<xref ref-type="bibr" rid="bibr84-1470320312459977">84</xref></sup> Studies have also reported that PPAR-γ agonists exhibit anti-inflammatory properties which are due to negative regulation of the expression of pro-inflammatory molecules such as interleukin-1b (IL-1b), IL-6 and TNF-α.<sup><xref ref-type="bibr" rid="bibr85-1470320312459977">85</xref>,<xref ref-type="bibr" rid="bibr86-1470320312459977">86</xref></sup> Further, PPAR-γ is being considered as a novel target to manage cognitive decline in AD patients.<sup><xref ref-type="bibr" rid="bibr20-1470320312459977">20</xref>,<xref ref-type="bibr" rid="bibr87-1470320312459977">87</xref>,<xref ref-type="bibr" rid="bibr88-1470320312459977">88</xref></sup> PPAR-γ agonists significantly reduced spatial memory impairment induced by the amyloid burden, Aβ aggregates, Aβ oligomers, astrocytic and microglia activation.<sup><xref ref-type="bibr" rid="bibr89-1470320312459977">89</xref></sup> Thus, prevention of the protective effect of lisinopril and telmisartan by BADGE suggests that, in addition to their antioxidative, anti-inflammatory and anticholinestrase activity, these drugs may also be acting through the PPAR-γ pathway and thus providing considerable protection in i.c.v. STZ induced dementia in mice.</p>
<p>Donepezil is a well-established drug for the management of dementia and is clinically used for memory deficits in AD patients. Further, previous reports from our laboratory and from others have shown the beneficial effect of donepezil in dementia of AD.<sup><xref ref-type="bibr" rid="bibr15-1470320312459977">15</xref>,<xref ref-type="bibr" rid="bibr16-1470320312459977">16</xref>,<xref ref-type="bibr" rid="bibr90-1470320312459977">90</xref>,<xref ref-type="bibr" rid="bibr91-1470320312459977">91</xref></sup> Therefore, donepezil has been taken as the positive control in this study.</p>
</sec>
<sec id="section24-1470320312459977" sec-type="conclusions">
<title>Conclusion</title>
<p>Hence on the basis of the above discussion it may be concluded that the ACEI, lisinopril, as well as the ARB, telmisartan, provide beneficial effects by improving learning, memory, brain cholinergic activity, inflammatory status and oxidative stress in i.c.v. STZ induced dementia of AD in mice. Furthermore, the beneficial effects of lisinopril and telmisartan also involve PPAR-γ modulation. Nevertheless further studies are needed to establish the full potential and mechanism of these drugs in dementia of AD type.</p>
</sec>
</body>
<back>
<ack><p>The authors are thankful to the Department of Pharmaceutical Sciences and Drug Research, Faculty of Medicine, Punjabi University, Patiala, Punjab, India for providing all the necessary facilities to conduct this research.</p></ack>
<fn-group>
<fn fn-type="conflict"><label>Conflict of interest</label><p>None declared.</p></fn>
<fn fn-type="financial-disclosure"><label>Funding</label><p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320312459977">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stephan</surname><given-names>BC</given-names></name>
<name><surname>Wells</surname><given-names>JC</given-names></name>
<name><surname>Brayne</surname><given-names>C</given-names></name>
<etal/></person-group>. <article-title>Increased fructose intake as a risk factor for dementia</article-title>. <source>J Gerontol A Biol Sci Med Sci</source> <year>2010</year>; <volume>65</volume>: <fpage>809</fpage>–<lpage>814</lpage>.</citation>
</ref>
<ref id="bibr2-1470320312459977">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamat</surname><given-names>SM</given-names></name>
<name><surname>Kamat</surname><given-names>AS</given-names></name>
<name><surname>Grossberg</surname><given-names>GT</given-names></name>
</person-group>. <article-title>Dementia risk prediction: are we there yet?</article-title> <source>Clin Geriatr Med</source> <year>2010</year>; <volume>26</volume>: <fpage>113</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr3-1470320312459977">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Strooper</surname><given-names>B</given-names></name>
</person-group>. <article-title>Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process</article-title>. <source>Physiol Rev</source> <year>2010</year>; <volume>90</volume>: <fpage>465</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr4-1470320312459977">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fagan</surname><given-names>AM</given-names></name>
<name><surname>Holtzman</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Cerebrospinal fluid biomarkers of Alzheimer’s disease</article-title>. <source>Biomark Med</source> <year>2010</year>; <volume>4</volume>: <fpage>51</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr5-1470320312459977">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Citron</surname><given-names>M</given-names></name>
</person-group>. <article-title>Alzheimer’s disease: strategies for disease modification</article-title>. <source>Nat Rev Drug Discov</source> <year>2010</year>; <volume>9</volume>: <fpage>387</fpage>–<lpage>398</lpage>.</citation>
</ref>
<ref id="bibr6-1470320312459977">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hampel</surname><given-names>H</given-names></name>
<name><surname>Frank</surname><given-names>R</given-names></name>
<name><surname>Broich</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Biomarkers for Alzheimer’s disease: academic, industry and regulatory perspectives</article-title>. <source>Nat Rev Drug Discov</source> <year>2010</year>; <volume>9</volume>: <fpage>560</fpage>–<lpage>574</lpage>.</citation>
</ref>
<ref id="bibr7-1470320312459977">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cagnoni</surname><given-names>F</given-names></name>
<name><surname>Njwe</surname><given-names>CA</given-names></name>
<name><surname>Zaninelli</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination</article-title>. <source>Vasc Health Risk Manag</source> <year>2010</year>; <volume>6</volume>: <fpage>549</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr8-1470320312459977">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kehoe</surname><given-names>PG</given-names></name>
<name><surname>Wilcock</surname><given-names>GK</given-names></name>
</person-group>. <article-title>Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease?</article-title> <source>Lancet Neurol</source> <year>2007</year>; <volume>6</volume>: <fpage>373</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr9-1470320312459977">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciobica</surname><given-names>A</given-names></name>
<name><surname>Bild</surname><given-names>W</given-names></name>
<name><surname>Hritcu</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia</article-title>. <source>Acta Neurol Belg</source> <year>2009</year>; <volume>109</volume>: <fpage>171</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr10-1470320312459977">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Li</surname><given-names>NC</given-names></name>
<name><surname>Lee</surname><given-names>A</given-names></name>
<name><surname>Whitmer</surname><given-names>RA</given-names></name>
<etal/></person-group>. <article-title>Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis</article-title>. <source>BMJ</source> <year>2010</year>; <volume>340</volume>: <fpage>b5465</fpage>.</citation>
</ref>
<ref id="bibr11-1470320312459977">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yamada</surname><given-names>K</given-names></name>
<name><surname>Uchida</surname><given-names>S</given-names></name>
<name><surname>Takahashi</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease</article-title>. <source>Brain Res</source> <year>2010</year>; <volume>1352</volume>: <fpage>176</fpage>–<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr12-1470320312459977">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hajjar</surname><given-names>IM</given-names></name>
<name><surname>Keown</surname><given-names>M</given-names></name>
<name><surname>Lewis</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Angiotensin converting enzyme inhibitors and cognitive and functional decline in patients with Alzheimer’s disease: an observational study</article-title>. <source>Am J Alzheimers Dis Other Demen</source> <year>2008</year>; <volume>23</volume>; <fpage>77</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr13-1470320312459977">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horiuchi</surname><given-names>M</given-names></name>
<name><surname>Mogi</surname><given-names>M</given-names></name>
</person-group>. <article-title>Roles of activation of angiotensin II receptor subtypes in ischemic brain damage and cognitive function</article-title>. <source>Br J Pharmacol</source> <year>2011</year>; <volume>163</volume>: <fpage>1122</fpage>–<lpage>1130</lpage>.</citation>
</ref>
<ref id="bibr14-1470320312459977">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zou</surname><given-names>K</given-names></name>
<name><surname>Yamaguchi</surname><given-names>H</given-names></name>
<name><surname>Akatsu</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition</article-title>. <source>J Neurosci</source> <year>2007</year>; <volume>27</volume>: <fpage>8628</fpage>–<lpage>8635</lpage>.</citation>
</ref>
<ref id="bibr15-1470320312459977">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>B</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Singh</surname><given-names>M</given-names></name>
</person-group>. <article-title>Modulation of celecoxib and streptozotocin-induced experimental dementia of Alzheimer’s disease type by pitavastatin and donepezil</article-title>. <source>J Psychopharmacol</source> <year>2008</year>; <volume>22</volume>: <fpage>162</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr16-1470320312459977">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>B</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Exploration of HIV protease inhibitor indinavir as a memory restorative agent in experimental induced dementia</article-title>. <source>Pharmacol Biochem Behav</source> <year>2008</year>; <volume>89</volume>: <fpage>535</fpage>–<lpage>545</lpage>.</citation>
</ref>
<ref id="bibr17-1470320312459977">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Blanco</surname><given-names>A</given-names></name>
<name><surname>Alvarez</surname><given-names>S</given-names></name>
<name><surname>Fresno</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Amyloid-β induces cyclooxygenase-2 and PGE2 release in human astrocytes in NF-κ B dependent manner</article-title>. <source>J Alzheimers Dis</source> <year>2010</year>; <volume>22</volume>: <fpage>493</fpage>–<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr18-1470320312459977">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaur</surname><given-names>B</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Exploring mechanism of pioglitazone-induced memory restorative effect in experimental dementia</article-title>. <source>Fundam Clin Pharmacol</source> <year>2009</year>; <volume>23</volume>: <fpage>557</fpage>–<lpage>566</lpage>.</citation>
</ref>
<ref id="bibr19-1470320312459977">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Escribano</surname><given-names>L</given-names></name>
<name><surname>Simón</surname><given-names>AM</given-names></name>
<name><surname>Gimeno</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Telmisartan rescues memory impairment in Alzheimer’s transgenic mice: mechanisms involving a reduced amyloid and tau pathology</article-title>. <source>Neuropsychopharmacology</source> <year>2010</year>; <volume>35</volume>: <fpage>1593</fpage>–<lpage>1604</lpage>.</citation>
</ref>
<ref id="bibr20-1470320312459977">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landreth</surname><given-names>G</given-names></name>
<name><surname>Jiang</surname><given-names>Q</given-names></name>
<name><surname>Mandrekar</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>PPAR gamma agonists as therapeutics for the treatment of Alzheimer’s disease</article-title>. <source>Neurotherapeutics</source> <year>2008</year>; <volume>5</volume>: <fpage>481</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr21-1470320312459977">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kaundal</surname><given-names>RK</given-names></name>
<name><surname>Sharma</surname><given-names>SS</given-names></name>
</person-group>. <article-title>Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents</article-title>. <source>Drug News Perspect</source> <year>2010</year>; <volume>23</volume>: <fpage>241</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr22-1470320312459977">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Napolitano</surname><given-names>M</given-names></name>
<name><surname>Costa</surname><given-names>L</given-names></name>
<name><surname>Palermo</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington’s disease</article-title>. <source>Brain Res Bull</source> <year>2011</year>; <volume>85</volume>: <fpage>231</fpage>–<lpage>237</lpage>.</citation>
</ref>
<ref id="bibr23-1470320312459977">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fouad</surname><given-names>AA</given-names></name>
<name><surname>Al-Sultan</surname><given-names>AI</given-names></name>
<name><surname>Yacoubi</surname><given-names>MT</given-names></name>
<etal/></person-group>. <article-title>Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration</article-title>. <source>Eur J Pharmacol</source> <year>2010</year>; <volume>637</volume>: <fpage>162</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr24-1470320312459977">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jermendy</surname><given-names>G</given-names></name>
</person-group>. <article-title>Is type-2 diabetes mellitus preventable?</article-title> <source>Orv Hetil</source> <year>2003</year>;<volume>144</volume>: <fpage>1909</fpage>–<lpage>1917</lpage>.</citation>
</ref>
<ref id="bibr25-1470320312459977">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hamed</surname><given-names>AA</given-names></name>
<name><surname>Malek</surname><given-names>HA</given-names></name>
</person-group>. <article-title>Effect of telmisartan in experimentally induced diabetetes mellitus in rats</article-title>. <source>Int J Health Sci (Qassim)</source> <year>2007</year>; <volume>1</volume>: <fpage>249</fpage>–<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr26-1470320312459977">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsumura</surname><given-names>T</given-names></name>
<name><surname>Kinoshita</surname><given-names>H</given-names></name>
<name><surname>Ishii</surname><given-names>N</given-names></name>
<etal/></person-group>. <article-title>Telmisartan exerts antiatherosclerotic effects by activating peroxisome proliferator-activated receptor-{gamma} in macrophages</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2011</year>; <volume>31</volume>: <fpage>1268</fpage>–<lpage>1275</lpage>.</citation>
</ref>
<ref id="bibr27-1470320312459977">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lakshmanan</surname><given-names>AP</given-names></name>
<name><surname>Watanabe</surname><given-names>K</given-names></name>
<name><surname>Thandavarayan</surname><given-names>RA</given-names></name>
<etal/></person-group>. <article-title>Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1–7) mas receptor expression associated with its PPAR-γ agonist action</article-title>. <source>Free Radic Res</source> <year>2011</year>; <volume>45</volume>: <fpage>575</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr28-1470320312459977">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Morris</surname><given-names>RGM</given-names></name>
</person-group>. <article-title>Development of a water maze producer for studying spatial learning in the rats</article-title>. <source>J Neurosci Meth</source> <year>1984</year>; <volume>11</volume>: <fpage>47</fpage>–<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr29-1470320312459977">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharma</surname><given-names>B</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
</person-group>. <article-title>Pitavastatin and 4′-hydroxy-3′-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes</article-title>. <source>Curr Neurovasc Res</source> <year>2010</year>; <volume>7</volume>: <fpage>180</fpage>–<lpage>191</lpage>.</citation>
</ref>
<ref id="bibr30-1470320312459977">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ellman</surname><given-names>GL</given-names></name>
<name><surname>Courtney</surname><given-names>DK</given-names></name>
<name><surname>Andres</surname><given-names>V</given-names></name>
<etal/></person-group>. <article-title>A new and rapid colorimeteric determination of acetylcholinesterase activity</article-title>. <source>Biochem Pharmacol</source> <year>1961</year>; <volume>7</volume>: <fpage>88</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr31-1470320312459977">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Voss</surname><given-names>G</given-names></name>
<name><surname>Sachsse</surname><given-names>K</given-names></name>
</person-group>. <article-title>Red cell and plasma cholinesterase activities in microsamples of human and animal blood determined simultaneously by a modified acetylcholine/DTNB procedure</article-title>. <source>Toxicol Appl Pharmacol</source> <year>1970</year>; <volume>16</volume>: <fpage>764</fpage>–<lpage>772</lpage>.</citation>
</ref>
<ref id="bibr32-1470320312459977">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Green</surname><given-names>LC</given-names></name>
<name><surname>Wagner</surname><given-names>DA</given-names></name>
<name><surname>Glogowski</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids</article-title>. <source>Anal Biochem</source> <year>1982</year>; <volume>126</volume>: <fpage>131</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr33-1470320312459977">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grisham</surname><given-names>MB</given-names></name>
<name><surname>Benoit</surname><given-names>JN</given-names></name>
<name><surname>Granger</surname><given-names>DN</given-names></name>
</person-group>. <article-title>Assessment of leukocyte involvement during ischemia and reperfusion of intestine</article-title>. <source>Methods Enzymol</source> <year>1990</year>; <volume>186</volume>: <fpage>729</fpage>–<lpage>742</lpage>.</citation>
</ref>
<ref id="bibr34-1470320312459977">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohokawa</surname><given-names>H</given-names></name>
<name><surname>Ohishi</surname><given-names>N</given-names></name>
<name><surname>Yagi</surname><given-names>K</given-names></name>
</person-group>. <article-title>Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction</article-title>. <source>Anal Biochem</source> <year>1979</year>; <volume>95</volume>: <fpage>351</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr35-1470320312459977">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beutler</surname><given-names>E</given-names></name>
<name><surname>Duron</surname><given-names>O</given-names></name>
<name><surname>Kelly</surname><given-names>B</given-names></name>
</person-group>. <article-title>Improved method for the determination of blood glutathione</article-title>. <source>J Lab Clinical Med</source> <year>1963</year>; <volume>61</volume>: <fpage>882</fpage>–<lpage>888</lpage>.</citation>
</ref>
<ref id="bibr36-1470320312459977">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lowry</surname><given-names>OH</given-names></name>
<name><surname>Rosebrough</surname><given-names>NJ</given-names></name>
<name><surname>Far</surname><given-names>AL</given-names></name>
<etal/></person-group>. <article-title>Protein measurement with folin-phenol reagent</article-title>. <source>J Biol Chem</source> <year>1951</year>; <volume>193</volume>: <fpage>265</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr37-1470320312459977">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hou</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>L</given-names></name>
<etal/></person-group>. <article-title>Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease</article-title>. <source>Chin Med J</source> <year>2008</year>; <volume>121</volume>: <fpage>2320</fpage>–<lpage>2323</lpage>.</citation>
</ref>
<ref id="bibr38-1470320312459977">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsukuda</surname><given-names>K</given-names></name>
<name><surname>Mogi</surname><given-names>M</given-names></name>
<name><surname>Iwanami</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation</article-title>. <source>Hypertension</source> <year>2009</year>; <volume>54</volume>: <fpage>782</fpage>–<lpage>787</lpage>.</citation>
</ref>
<ref id="bibr39-1470320312459977">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mogi</surname><given-names>M</given-names></name>
<name><surname>Li</surname><given-names>JM</given-names></name>
<name><surname>Tsukuda</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Telmisartan prevented cognitive decline partly due to PPAR-gamma activation</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2008</year>; <volume>375</volume>: <fpage>446</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr40-1470320312459977">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>SL</given-names></name>
<name><surname>Yang</surname><given-names>XJ</given-names></name>
<name><surname>Liu</surname><given-names>TF</given-names></name>
<etal/></person-group>. <article-title>Effect and mechanism of jiannao yizhi decoction on learning and memory in rats with similar Alzheimer’s disease</article-title>. <source>Zhongguo Zhong Xi Yi Jie He Za Zhi</source> <year>2008</year>; <volume>28</volume>: <fpage>529</fpage>–<lpage>531</lpage>.</citation>
</ref>
<ref id="bibr41-1470320312459977">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rinwa</surname><given-names>P</given-names></name>
<name><surname>Kaur</surname><given-names>B</given-names></name>
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
<etal/></person-group>. <article-title>Involvement of PPAR-gamma in curcumin-mediated beneficial effects in experimental dementia</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source> <year>2010</year>; <volume>381</volume>: <fpage>529</fpage>–<lpage>539</lpage>.</citation>
</ref>
<ref id="bibr42-1470320312459977">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parle</surname><given-names>M</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
</person-group>. <article-title>Reversal of memory deficits by atorvastatin and simvastatin in rats</article-title>. <source>Yakugaku Zasshi</source> <year>2007</year>; <volume>127</volume>: <fpage>1125</fpage>–<lpage>1137</lpage>.</citation>
</ref>
<ref id="bibr43-1470320312459977">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Packard</surname><given-names>MG</given-names></name>
<name><surname>Teather</surname><given-names>LA</given-names></name>
<name><surname>Bazan</surname><given-names>NG</given-names></name>
</person-group>. <article-title>Effect of intra-striated injectins of platelet-activating factor and PAF antagonist BN 52021 on memory</article-title>. <source>Neurobiol Learn Mem</source> <year>1996</year>; <volume>66</volume>: <fpage>176</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr44-1470320312459977">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camarasa</surname><given-names>J</given-names></name>
<name><surname>Rodrigo</surname><given-names>T</given-names></name>
<name><surname>Pubill</surname><given-names>D</given-names></name>
<etal/></person-group>. <article-title>Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats</article-title>. <source>Pharmacol Res</source> <year>2010</year>; <volume>62</volume>: <fpage>450</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr45-1470320312459977">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tota</surname><given-names>S</given-names></name>
<name><surname>Awasthi</surname><given-names>H</given-names></name>
<name><surname>Kamat</surname><given-names>PK</given-names></name>
<etal/></person-group>. <article-title>Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice</article-title>. <source>Behav Brain Res</source> <year>2010</year>; <volume>209</volume>: <fpage>73</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr46-1470320312459977">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lannert</surname><given-names>H</given-names></name>
<name><surname>Hoyer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats</article-title>. <source>Behav Neurosci</source> <year>1998</year>; <volume>112</volume>: <fpage>1199</fpage>–<lpage>1208</lpage>.</citation>
</ref>
<ref id="bibr47-1470320312459977">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mayer</surname><given-names>G</given-names></name>
<name><surname>Nitsch</surname><given-names>R</given-names></name>
<name><surname>Hoyer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Effects of changes in peripheral and cerebral glucose metabolism on locomotor activity, learning and memory in adult male rats</article-title>. <source>Brain Res</source> <year>1990</year>; <volume>532</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr48-1470320312459977">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoyer</surname><given-names>S</given-names></name>
<name><surname>Muller</surname><given-names>D</given-names></name>
<name><surname>Plaschke</surname><given-names>K</given-names></name>
</person-group>. <article-title>Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism</article-title>. <source>J Neural Transm</source> <year>1994</year>; <volume>44</volume>: <fpage>S259</fpage>–<lpage>S268</lpage>.</citation>
</ref>
<ref id="bibr49-1470320312459977">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoyer</surname><given-names>S</given-names></name>
</person-group>. <article-title>The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late onset sporadic Alzheimer’s disease (SAD). A mini review</article-title>. <source>J Neural Transm</source> <year>2000</year>; <volume>109</volume>: <fpage>991</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr50-1470320312459977">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoyer</surname><given-names>S</given-names></name>
</person-group>. <article-title>The brain insulin signal transduction system and sporadic (type II) Alzheimer’ s disease: an update</article-title>. <source>J Neural Transm</source> <year>2000</year>; <volume>109</volume>: <fpage>S341</fpage>–<lpage>S360</lpage>.</citation>
</ref>
<ref id="bibr51-1470320312459977">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agrawal</surname><given-names>R</given-names></name>
<name><surname>Tyagi</surname><given-names>E</given-names></name>
<name><surname>Shukla</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>A Study of brain insulin receptors, AChE activity and oxidative stress in rat model of ICV STZ induced dementia</article-title>. <source>Neuropharmacology</source> <year>2009</year>; <volume>56</volume>: <fpage>779</fpage>–<lpage>787</lpage>.</citation>
</ref>
<ref id="bibr52-1470320312459977">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shoham</surname><given-names>S</given-names></name>
<name><surname>Bejar</surname><given-names>C</given-names></name>
<name><surname>Kovalev</surname><given-names>E</given-names></name>
<etal/></person-group>. <article-title>Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats</article-title>. <source>Exp Neurol</source> <year>2003</year>; <volume>184</volume>: <fpage>1043</fpage>–<lpage>1052</lpage>.</citation>
</ref>
<ref id="bibr53-1470320312459977">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grünblatt</surname><given-names>E</given-names></name>
<name><surname>Koutsilieri</surname><given-names>E</given-names></name>
<name><surname>Hoyer</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat</article-title>. <source>J Alzheimers Dis</source> <year>2006</year>; <volume>9</volume>: <fpage>261</fpage>–<lpage>271</lpage>.</citation>
</ref>
<ref id="bibr54-1470320312459977">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ceriello</surname><given-names>A</given-names></name>
<name><surname>Quagliaro</surname><given-names>L</given-names></name>
<name><surname>D’Amico</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat</article-title>. <source>Diabetes</source> <year>2002</year>; <volume>51</volume>: <fpage>1076</fpage>–<lpage>1082</lpage>.</citation>
</ref>
<ref id="bibr55-1470320312459977">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spitaler</surname><given-names>MM</given-names></name>
<name><surname>Graier</surname><given-names>WF</given-names></name>
</person-group>. <article-title>Vascular targets of redox signalling in diabetes mellitus</article-title>. <source>Diabetologia</source> <year>2002</year>; <volume>45</volume>: <fpage>476</fpage>–<lpage>494</lpage>.</citation>
</ref>
<ref id="bibr56-1470320312459977">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kumaran</surname><given-names>D</given-names></name>
<name><surname>Udayabanu</surname><given-names>M</given-names></name>
<name><surname>Kumar</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats</article-title>. <source>Neuroscience</source> <year>2008</year>; <volume>155</volume>: <fpage>626</fpage>–<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr57-1470320312459977">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savaskan</surname><given-names>E</given-names></name>
</person-group>. <article-title>The role of the brain renin-angiotensin system in neurodegenerative disorders</article-title>. <source>Curr Alzheimer Res</source> <year>2005</year>; <volume>2</volume>: <fpage>29</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr58-1470320312459977">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sukhanov</surname><given-names>S</given-names></name>
<name><surname>Semprun-Prieto</surname><given-names>L</given-names></name>
<name><surname>Yoshida</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Angiotensin II, oxidative stress and skeletal muscle wasting</article-title>. <source>Am J Med Sci</source> <year>2011</year>; <volume>342</volume>: <fpage>143</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr59-1470320312459977">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>JM</given-names></name>
<name><surname>Uehara</surname><given-names>Y</given-names></name>
<name><surname>Choi</surname><given-names>YJ</given-names></name>
<etal/></person-group>. <article-title>Mechanism of attenuation of pro-inflammatory Ang II-induced NF-κB activation by genistein in the kidneys of male rats during aging</article-title>. <source>Biogerontology</source> <year>2011</year>; <volume>12</volume>: <fpage>537</fpage>–<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr60-1470320312459977">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yasar</surname><given-names>S</given-names></name>
<name><surname>Zhou</surname><given-names>J</given-names></name>
<name><surname>Varadhan</surname><given-names>R</given-names></name>
<etal/></person-group>. <article-title>The use of angiotensin-converting enzyme inhibitors and diuretics is associated with a reduced incidence of impairment on cognition in elderly women</article-title>. <source>Clin Pharmacol Ther</source> <year>2008</year>; <volume>84</volume>: <fpage>119</fpage>–<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr61-1470320312459977">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>JM</given-names></name>
<name><surname>Barnes</surname><given-names>NM</given-names></name>
<name><surname>Costall</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Angiotensin II inhibits the release of [3H] acetylcholine from rat entorhinal cortex in vitro</article-title>. <source>Brain Res</source> <year>1989</year>; <volume>491</volume>: <fpage>136</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr62-1470320312459977">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>JM</given-names></name>
<name><surname>Barnes</surname><given-names>NM</given-names></name>
<name><surname>Costall</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition</article-title>. <source>Brain Res</source> <year>1990</year>; <volume>507</volume>: <fpage>341</fpage>–<lpage>343</lpage>.</citation>
</ref>
<ref id="bibr63-1470320312459977">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yaffe</surname><given-names>K</given-names></name>
<name><surname>Lindquist</surname><given-names>K</given-names></name>
<name><surname>Penninx</surname><given-names>BW</given-names></name>
<etal/></person-group>. <article-title>Inflammatory markers and cognition in well-functioning African-American and white elders</article-title>. <source>Neurology</source> <year>2003</year>; <volume>61</volume>: <fpage>76</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr64-1470320312459977">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tuppo</surname><given-names>EE</given-names></name>
<name><surname>Arias</surname><given-names>HR</given-names></name>
</person-group>. <article-title>The role of inflammation in Alzheimer’s disease</article-title>. <source>Int J Biochem Cell Biol</source> <year>2005</year>; <volume>37</volume>: <fpage>289</fpage>–<lpage>305</lpage>.</citation>
</ref>
<ref id="bibr65-1470320312459977">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haraguchi</surname><given-names>T</given-names></name>
<name><surname>Takasaki</surname><given-names>K</given-names></name>
<name><surname>Naito</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism</article-title>. <source>Neurosci Lett</source> <year>2009</year>; <volume>464</volume>: <fpage>151</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr66-1470320312459977">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ismail</surname><given-names>H</given-names></name>
<name><surname>Mitchell</surname><given-names>R</given-names></name>
<name><surname>McFarlane</surname><given-names>SI</given-names></name>
<etal/></person-group>. <article-title>Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering</article-title>. <source>Curr Diab Rep</source> <year>2010</year>; <volume>10</volume>: <fpage>32</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr67-1470320312459977">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kasahara</surname><given-names>Y</given-names></name>
<name><surname>Taguchi</surname><given-names>A</given-names></name>
<name><surname>Uno</surname><given-names>H</given-names></name>
<etal/></person-group>. <article-title>Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia</article-title>. <source>Brain Res</source> <year>2010</year>; <volume>1340</volume>: <fpage>70</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr68-1470320312459977">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hwang</surname><given-names>SJ</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
<name><surname>Shim</surname><given-names>JW</given-names></name>
<etal/></person-group>. <article-title>Peroxisome proliferator-activated receptor-gamma expression in the lung tissue of obese rats</article-title>. <source>Yonsei Med J</source> <year>2011</year>; <volume>52</volume>: <fpage>495</fpage>–<lpage>501</lpage>.</citation>
</ref>
<ref id="bibr69-1470320312459977">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohrui</surname><given-names>T</given-names></name>
<name><surname>Matsui</surname><given-names>T</given-names></name>
<name><surname>Yamaya</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Angiotensin-converting enzyme inhibitors and incidence of Alzheimer’s disease in Japan</article-title>. <source>J Am Geriatr Soc</source> <year>2004</year>; <volume>52</volume>: <fpage>649</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr70-1470320312459977">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>JM</given-names></name>
<name><surname>Leenen</surname><given-names>FH</given-names></name>
</person-group>. <article-title>Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats</article-title>. <source>Am J Hypertens</source> <year>2005</year>; <volume>18</volume>: <fpage>158</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr71-1470320312459977">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wyss</surname><given-names>JM</given-names></name>
<name><surname>Kadish</surname><given-names>I</given-names></name>
<name><surname>Van Groen</surname><given-names>T</given-names></name>
</person-group>. <article-title>Age-related decline in spatial learning and memory: attenuation by captopril</article-title>. <source>Clin Exp Hypertens</source> <year>2003</year>; <volume>25</volume>: <fpage>455</fpage>–<lpage>474</lpage>.</citation>
</ref>
<ref id="bibr72-1470320312459977">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haraguchi</surname><given-names>T</given-names></name>
<name><surname>Iwasaki</surname><given-names>K</given-names></name>
<name><surname>Takasaki</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Telmisartan, a partial agonist of peroxisome proliferator-activated receptor gamma, improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia</article-title>. <source>Brain Res</source> <year>2010</year>; <volume>1353</volume>: <fpage>125</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr73-1470320312459977">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurihara</surname><given-names>T</given-names></name>
<name><surname>Ozawa</surname><given-names>Y</given-names></name>
<name><surname>Shinoda</surname><given-names>K</given-names></name>
<etal/></person-group>. <article-title>Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation</article-title>. <source>Invest Ophthalmol Vis Sci</source> <year>2006</year>; <volume>47</volume>: <fpage>5545</fpage>–<lpage>5552</lpage>.</citation>
</ref>
<ref id="bibr74-1470320312459977">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kobayashi</surname><given-names>T</given-names></name>
<name><surname>Kawamata</surname><given-names>T</given-names></name>
<name><surname>Shibata</surname><given-names>N</given-names></name>
<etal/></person-group>. <article-title>Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A (2) level in experimental stroke</article-title>. <source>J Neurotrauma</source> <year>2009</year>; <volume>26</volume>: <fpage>2355</fpage>–<lpage>2364</lpage>.</citation>
</ref>
<ref id="bibr75-1470320312459977">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jung</surname><given-names>KH</given-names></name>
<name><surname>Chu</surname><given-names>K</given-names></name>
<name><surname>Lee</surname><given-names>ST</given-names></name>
<etal/></person-group>. <article-title>Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage</article-title>. <source>J Pharmacol Exp Ther</source> <year>2007</year>; <volume>322</volume>: <fpage>1051</fpage>–<lpage>1058</lpage>.</citation>
</ref>
<ref id="bibr76-1470320312459977">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>T</given-names></name>
<name><surname>Gilani</surname><given-names>AH</given-names></name>
</person-group>. <article-title>Inhibitory effect of curcuminoids on acetylcholinesterase activity and attenuation of scopolamine-induced amnesia may explain medicinal use of turmeric in Alzheimer’s disease</article-title>. <source>Pharmacol Biochem Behav</source> <year>2009</year>; <volume>91</volume>: <fpage>554</fpage>–<lpage>559</lpage>.</citation>
</ref>
<ref id="bibr77-1470320312459977">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hajjar</surname><given-names>I</given-names></name>
<name><surname>Hart</surname><given-names>M</given-names></name>
<name><surname>Milberg</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition</article-title>. <source>BMC Geriatr</source> <year>2009</year>; <volume>9</volume>: <fpage>48</fpage>.</citation></ref>
<ref id="bibr78-1470320312459977">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>C</given-names></name>
<name><surname>Teo</surname><given-names>K</given-names></name>
<name><surname>Gao</surname><given-names>P</given-names></name>
<etal/></person-group>. <article-title>Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies</article-title>. <source>Lancet Neurol</source> <year>2011</year>; <volume>10</volume>: <fpage>43</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr79-1470320312459977">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fatehi-Hassanabad</surname><given-names>Z</given-names></name>
<name><surname>Tasker</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Peroxisome proliferator-activated receptors-gamma PPAR-gamma) activation confers functional neuroprotection in global ischemia</article-title>. <source>Neurotox Res</source> <year>2011</year>; <volume>19</volume>: <fpage>462</fpage>–<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr80-1470320312459977">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Glatz</surname><given-names>T</given-names></name>
<name><surname>Stock</surname><given-names>I</given-names></name>
<name><surname>Nguyen-Ngoc</surname><given-names>M</given-names></name>
<etal/></person-group>. <article-title>Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischemic brain</article-title>. <source>J Hypertens</source> <year>2010</year>; <volume>28</volume>: <fpage>1488</fpage>–<lpage>1497</lpage>.</citation>
</ref>
<ref id="bibr81-1470320312459977">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pereira</surname><given-names>MP</given-names></name>
<name><surname>Hurtado</surname><given-names>O</given-names></name>
<name><surname>Cárdenas</surname><given-names>A</given-names></name>
<etal/></person-group>. <article-title>Telmisartan and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms</article-title>. <source>J Cereb Blood Flow Metab</source> <year>2006</year>; <volume>26</volume>: <fpage>218</fpage>–<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr82-1470320312459977">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyong</surname><given-names>A</given-names></name>
<name><surname>Jadhav</surname><given-names>V</given-names></name>
<name><surname>Lee</surname><given-names>S</given-names></name>
<etal/></person-group>. <article-title>Telmisartan, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents</article-title>. <source>Brain Res</source> <year>2008</year>; <volume>1215</volume>: <fpage>218</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr83-1470320312459977">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Strong</surname><given-names>R</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Neuronal PPAR gamma deficiency increases susceptibility to brain damage after cerebral ischemia</article-title>. <source>J Neurosci</source> <year>2009</year>; <volume>29</volume>: <fpage>6186</fpage>–<lpage>6195</lpage>.</citation>
</ref>
<ref id="bibr84-1470320312459977">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nicolakakis</surname><given-names>N</given-names></name>
<name><surname>Aboulkassim</surname><given-names>T</given-names></name>
<name><surname>Ongali</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>Complete rescue of cerebrovascular function in aged Alzheimer’s disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist</article-title>. <source>J Neurosci</source> <year>2008</year>; <volume>28</volume>: <fpage>9287</fpage>–<lpage>9296</lpage>.</citation>
</ref>
<ref id="bibr85-1470320312459977">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Halvorsen</surname><given-names>B</given-names></name>
<name><surname>Heggen</surname><given-names>E</given-names></name>
<name><surname>Ueland</surname><given-names>T</given-names></name>
<etal/></person-group>. <article-title>Treatment with the PPAR gamma agonist telmisartan downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome</article-title>. <source>Eur J Endocrinol</source> <year>2010</year>; <volume>162</volume>: <fpage>267</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr86-1470320312459977">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Hu</surname><given-names>W</given-names></name>
<name><surname>Meng</surname><given-names>B</given-names></name>
<etal/></person-group>. <article-title>PPARgamma agonist telmisartan is neuroprotective after traumatic spinal cord injury via anti-inflammatory in adult rats</article-title>. <source>Neurol Res</source> <year>2010</year>; PMID: 20350367.</citation>
</ref>
<ref id="bibr87-1470320312459977">
<label>87.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Landreth</surname><given-names>G</given-names></name>
</person-group>. <article-title>Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer’s disease</article-title>. <source>Curr Alzheimer Res</source> <year>2007</year>; <volume>4</volume>: <fpage>159</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr88-1470320312459977">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sodhi</surname><given-names>RK</given-names></name>
<name><surname>Singh</surname><given-names>N</given-names></name>
<name><surname>Jaggi</surname><given-names>AS</given-names></name>
</person-group>. <article-title>Neuroprotective mechanisms of peroxisome proliferator-activated receptor agonists in Alzheimer’s disease</article-title>. <source>Naunyn Schmiedebergs Arch Pharmacol</source> <year>2011</year>; <volume>384</volume>: <fpage>115</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr89-1470320312459977">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Toledo</surname><given-names>EM</given-names></name>
<name><surname>Inestrosa</surname><given-names>NC</given-names></name>
</person-group>. <article-title>Activation of Wnt signaling by lithium and telmisartan reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease</article-title>. <source>Mol Psychiatry</source> <year>2010</year>; <volume>15</volume>: <fpage>272</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr90-1470320312459977">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dong</surname><given-names>H</given-names></name>
<name><surname>Yuede</surname><given-names>CM</given-names></name>
<name><surname>Coughlan</surname><given-names>CA</given-names></name>
<etal/></person-group>. <article-title>Effects of donepezil on amyloid-beta and synapse density in the Tg2576 mouse model of Alzheimer’s disease</article-title>. <source>Brain Res</source> <year>2009</year>; <volume>1303</volume>: <fpage>169</fpage>–<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr91-1470320312459977">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maelicke</surname><given-names>A</given-names></name>
<name><surname>Hoeffle-Maas</surname><given-names>A</given-names></name>
<name><surname>Ludwig</surname><given-names>J</given-names></name>
<etal/></person-group>. <article-title>Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy</article-title>. <source>J Mol Neurosci</source> <year>2010</year>; <volume>40</volume>: <fpage>135</fpage>–<lpage>137</lpage>.</citation>
</ref></ref-list>
</back>
</article>